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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 67, Revision 1 
(FGE.67Rev.1): 
Consideration of 40 furan-substituted aliphatic hydrocarbons, alcohols, 
aldehydes, ketones, carboxylic acids and related esters, sulfides, disulfides 
and ethers evaluated by JECFA at the 65th meeting (JECFA, 2006b) and re-
evaluated at the 69th meeting (JECFA, 2009c)1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to consider evaluations of flavouring substances assessed since 
2000 by the Joint FAO/WHO Expert Committee on Food Additives (the JECFA), and to decide 
whether further evaluation is necessary, as laid down in Commission Regulation (EC) No 1565/2000. 
The present consideration concerns a group of 33 furan-substituted aliphatic hydrocarbons, alcohols, 
aldehydes, ketones, carboxylic acids and related esters, sulfides, disulfides and ethers evaluated by the 
JECFA. In the present version of FGE.67 eight additional substances have been included. The 
substances were evaluated through a stepwise approach (the Procedure) that integrates information on 
structure-activity relationships, intake from current uses, toxicological threshold of concern, and 
available data on metabolism and toxicity. For twenty-two substances [FL-no: 13.029, 13.030, 13.045, 
13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.092, 13.101, 13.103, 13.105, 
13.106, 13.107, 13.123, 13.138, 13.148, 13.163 and 13.191] a concern for genotoxicity was raised and 
therefore these were not evaluated using the Procedure. The Panel concluded that 8 substances [FL-no: 
                                                     
 
1  On request from the Commission, Question No EFSA-Q-2011-00867, EFSA-Q-2011-00868, EFSA-Q-2011-00869, 
EFSA-Q-2011-00870, EFSA-Q-2011-00871, EFSA-Q-2011-00872, EFSA-Q-2011-00873, EFSA-Q-2011-00874, EFSA-
Q-2011-00875, EFSA-Q-2011-00876 adopted on 6 July 2011. 
2  Panel members: Arturo Anadon, Mona-Lise Binderup, Wilfried Bursch, Laurence Castle, Riccardo Crebelli, Karl-Heinz 
Engel, Roland Franz, Nathalie Gontard, Thomas Haertle, Trine Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean 
Claude Lhuguenot, Wim Mennes, Maria Rosaria Milana, Karla Pfaff, Kettil Svensson, Fidel Toldra, Rosemary Waring, 
Detlef Wölfle. Correspondence: cef-unit@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings for the preparation of 
this Opinion: Ulla Beckman Sundh, Vibe Beltoft, Wilfried Bursch, Angelo Carere, Riccardo Crebelli, Karl-Heinz Engel, 
Henrik Frandsen, Rainer Gürtler, Frances Hill, Trine Husøy, John Christian Larsen, Catherine Leclercq, Pia Lund, Wim 
Mennes, Gerard Mulder, Karin Nørby, Iona Pratt, Gerrit Speijers, Harriet Wallin and EFSA’s staff member Kim Rygaard 
Nielsen for the preparatory work on this scientific Opinion. 
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13.006, 13.021, 13.022, 13.023, 13.024, 13.074, 13.116 and 13.190] do not give rise to safety 
concerns at the levels of dietary intake, estimated on the basis of the MSDI approach. For one 
substance [FL-no: 13.058] additional toxicity data are requested. Besides the safety assessment of 
these substances, the specifications for the materials of commerce have been considered. For three 
substances [FL-no: 13.031, 13.045 and 13.047] data on specifications / stereoisomerism are missing. 
 
© European Food Safety Authority, 2011 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to consider the Joint FAO/WHO Expert 
Committee on Food Additives (the JECFA) evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) 
No 1565/2000. These flavouring substances are listed in the Register, which was adopted by 
Commission Decision 1999/217/EC and its consecutive amendments. 
The present Flavouring Group Evaluation deals with 39 substances, 38 substances of which were 
previously considered by the JECFA in a group of 40 furan-substituted aliphatic hydrocarbons, 
alcohols, aldehydes, ketones, carboxylic acids and related esters, sulfides, disulfides and ethers 
(JECFA, 2009a). One of these 40 substances [FL-no: 13.192] appeared to be a synonym of substance 
[FL-no: 13.178] which has already been evaluated in FGE.13Rev2. Therefore this substance [FL-no: 
13.192] will not be further considered in this FGE and should be removed from the Register. Another 
substance [FL-no: 13.176] will be evaluated in FGE.75 rather than in FGE.67, because of better 
structural similarity with candidate substances in FGE.75. Furthermore, one candidate substance [FL-
no: 13.031] from FGE.66Rev1 has been included in this revision of FGE.67, because this substance 
has better structural similarity to a candidate flavouring substance [FL-no: 13.074] in FGE.67 than to 
the other candidate flavouring substances in FGE.66Rev1. The flavouring substances considered in 
this FGE have been allocated to various subgroups, based on their chemical structures. 
Thirteen of the 15 substances in subgroups VI-A and VI-B are alpha,beta-unsaturated carbonyls, 
which have been evaluated by EFSA in FGE.19 context with respect to a concern for a possible 
genotoxic potential. This concern for genotoxicity could not be alleviated for the six substances in 
subgroup VI-A [FL-no: 13.034, 13.043, 13.044, 13.046, 13.137 and 13.150], corresponding to FGE.19 
subgroup 4.6 (EFSA, 2008b). These six substances were therefore not further considered in this FGE. 
The thirty-three candidate substances considered in this FGE [FL-no: 13.006, 13.021, 13.022, 13.023, 
13.024, 13.029, 13.030, 13.031, 13.045, 13.047, 13.052, 13.054, 13.058, 13.059, 13.061, 13.066, 
13.069, 13.070, 13.074, 13.083, 13.092, 13.101, 13.103, 13.105, 13.106, 13.107, 13.116, 13.123, 
13.138, 13.148, 13.163, 13.190 and 13.191] are structurally related to the group of 27 furfuryl and 
furan derivatives evaluated by EFSA in FGE.13Rev2. Part of the substances is also structurally related 
to a group of 33 sulphur-substituted furan derivatives used as flavouring agents, evaluated by EFSA in 
FGE.65 and another part is structurally related to 14 furfuryl derivatives evaluated in FGE.66Rev1 
(EFSA, 2009an; EFSA, 2011ad). 
The Panel agrees with the JECFA for 22 of the substances [FL-no: 13.029, 13.030, 13.045, 13.052, 
13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.092, 13.101, 13.103, 13.105, 13.106, 
13.107, 13.123, 13.138, 13.148, 13.163 and 13.191] that these substances cannot be evaluated through 
the Procedure, based on concerns with respect to genotoxicity. 
In line with the approaches taken in previous FGEs (FGE.13Rev2, FGE.65 and FGE.66Rev1), the 
Panel considers that 11 substances [FL-no: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 
13.058, 13.074, 13.116 and 13.190] can be evaluated using the Procedure. 
It was concluded for ten substances [FL-no: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 
13.074, 13.116 and 13.190], that they would be of no safety concern at their estimated intake levels 
based on the MSDI approach. For the remaining substance [FL-no: 13.058] this conclusion could not 
be drawn due to lack of an adequate NOAEL. 
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For all 33 substances use levels are needed to calculate the mTAMDIs in order to identify those 
flavouring substances that need more refined exposure assessment and to finalise the evaluation. 
In order to determine whether the conclusion for the evaluated substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity are available for 30 of the 33 substances. Information 
on stereoisomeric composition has not been submitted for [FL-no: 13.047]. Information on solubility 
in water is missing for [FL-no: 13.045] and information on melting point is missing for [FL-no: 
13.031]. 
Thus, for 25 of the 33 substances considered in this FGE the Panel has reservations. For three 
substances [FL-no: 13.031, 13.045 and 13.047] data on specifications / stereoisomerism are missing. 
For 23 substances [FL-no: 13.029, 13.030, 13.045, 13.052, 13.054, 13.058, 13.059, 13.061, 13.066, 
13.069, 13.070, 13.083, 13.092, 13.101, 13.103, 13.105, 13.106, 13.107, 13.123, 13.138, 13.148, 
13.163 and 13.191] the Panel concluded that additional toxicity / genotoxicity data are required.  
For the remaining eight of these 33 furan derivatives [FL-no: 13.006, 13.021, 13.022, 13.023, 13.024, 
13.074, 13.116 and 13.190] the Panel concluded that they would be of “no safety concern at estimated 
levels of intake as flavouring substances” based on the MSDI approach. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances, the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a).  
Commission Regulation (EC) No 1565/2000 lays down that substances that are contained in the 
Register and will be classified in the future by the Joint FAO/WHO Expert Committee on Food 
Additives (the JECFA) so as to present no safety concern at current levels of intake will be considered 
by the European Food Safety Authority (EFSA), who may then decide that no further evaluation is 
necessary. 
In the period 2000 – 2008, during its 55th, 57th, 59th, 61st, 63rd, 65th, 68th and 69th meetings, the JECFA 
evaluated about 1000 substances, which are in the EU Register. 
TERMS OF REFERENCE 
EFSA is requested to consider the JECFA evaluations of flavouring substances assessed since 2000, 
and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) 
No 1565/2000 (EC, 2000a). These flavouring substances are listed in the Register which was adopted 
by Commission Decision 1999/217 EC (EC, 1999a) and its consecutive amendments. 
ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), hereafter named the “EFSA Procedure”. 
This Procedure is based on the Opinion of the Scientific Committee on Food (SCF, 1999a), which has 
been derived from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on 
Food Additives (JECFA, 1995; JECFA, 1996a; JECFA, 1997a; JECFA, 1999b), hereafter named the 
“JECFA Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids (the Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be put through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
Flavouring Group Evaluation 67, Revision 1
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by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006c). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram/person/day as part of the evaluation 
procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 microgram per 
person per day would not be expected to present a safety concern. The Committee recommended that 
the Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be 
amended to include the last step on the right-hand side of the original procedure (“Do the condition of 
use result in an intake greater than 1.5 microgram per day?”) (JECFA, 1999b).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 microgram per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999a), the Panel has in its evaluation focussed on a 
possible genotoxic potential of the flavouring substances or of structurally related substances. 
Generally, substances for which the Panel has concluded that there is an indication of genotoxic 
potential in vitro, will not be evaluated using the EFSA Procedure until further genotoxicity data are 
provided. Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated 
through the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
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Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
HISTORY OF THE EVALUATION 
FGE Opinion adopted 
by EFSA 
Link No. of candidate 
substances 
FGE.67 26 November 2009 http://www.efsa.europa.eu/en/scdocs/scdoc/1404.htm 25 
FGE.67Rev1 6 July 2011  33 
 
The present revision of FGE.67, FGE.67Rev1 includes the consideration of additional eight 
substances. The sub-grouping of the two ketones [FL-no: 13.045 and 13.138] has been changed from 
subgroup III  to subgroup VI-B. Due to a newly identified concern for genotoxicity, the evaluation of 
these two ketones has been revised since the previous version of FGE.67. 
Seven of the eight additional substances [FL-no: 13.054, 13.066, 13.070, 13.083, 13.101, 13.105, 
13.163] are alpha,beta-unsaturated ketones originally allocated to FGE.19 subgroup 4.5 (FGE.221) 
(EFSA 2008b). This structural characteristic is a known alert for genotoxicity, which may preclude the 
evaluation of substances through the Procedure. EFSA concluded in November 2008 that the 
alpha,beta-unsaturated structure in conjugation with an aromatic ring system, which is present in these 
seven substances, is comparable to acetophenone, i.e. no longer considered a structural alert for 
genotoxicity (EFSA, 2011ac). These seven substances are shown in Table 1.1.2, Subgroup VI-B. 
The eighth substance, 2-benzofurancarboxaldehyde [FL-no: 13.031], is an alpha,beta-unsaturated 
aldehyde originally allocated to FGE.19 subgroup 4.3 (FGE.219) (EFSA 2008b). Also for this 
substance the alpha,beta-unsaturated structure is in conjugation with an aromatic ring system which is 
comparable to the situation in benzaldehyde for which no genotoxic concern is present (EFSA, 
2011ac). Accordingly, this substance can also be evaluated using the Procedure. Although the 
substance originally was allocated by the JECFA to the group of furfuryl alcohol derivatives covered 
in FGE.66Rev1, the Panel considered that the substance belongs to the benzofurans in group V-B of 
the present FGE.67 (see Table 1.1.2).   
1. Presentation of the Substances in the JECFA Flavouring Group 
1.1. Description 
The JECFA has evaluated a group of 40 diverse furan derivatives, first at their 65th meeting (JECFA, 
2006b) where a request for additional data was expressed. The furan group was on the agenda again at 
the 69th JECFA meeting (JECFA, 2009c) where additional data had been provided. 
1.1.1. JECFA Status 
The JECFA expressed at its 69th meeting (JECFA, 2009a): 
“At its sixty-fifth meeting (JECFA, 2006b), the JECFA reviewed a group of 40 furan-substituted 
aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulfides, 
disulfides and ethers. The JECFA at that meeting took note of the extensive evidence for the 
genotoxicity of several members of this group of flavouring agents related to furan, including the 
clastogenicity of 2-furyl methyl ketone (JECFA-no: 1503) (2-acetylfuran, [FL-no: 13.054]) in mouse 
bone marrow. This substance accounts for 87 - 96 % of total exposure to this group of flavouring 
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agents. Noting also that furan is carcinogenic and is known to undergo epoxidation and ring opening 
to form a reactive 2-ene-1,4-dicarbonyl intermediate, the JECFA at its sixty-fifth meeting expressed 
concern that the observed genotoxicity might be due to formation of a reactive metabolite. Few data 
on genotoxicity in vivo were available, and specific assays to address potential carcinogenicity in vivo 
were lacking. The JECFA at its sixty-fifth meeting therefore concluded that the Procedure for the 
Safety Evaluation of Flavouring Agents could not be applied to this group because of the above 
concerns. It was also concluded that studies of metabolism and in vivo assays for deoxyribonucleic 
acid (DNA) reactivity, mutagenicity and carcinogenic potential of members of this group with 
representative structures would assist in resolving the concerns (JECFA, 2006b). 
Additional studies of genotoxicity in vitro and in vivo with 2-furyl methyl ketone [FL-no: 13.054] 
were available to the Committee (the JECFA) at its present meeting (Durward, 2007a, 2007b; Sujatha, 
2007). The Committee (JECFA, 2009c) included the new studies in its re-evaluation of the group of 
40 furan-substituted aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related 
esters, sulfides, disulfides and ethers.”  
“The new data on 2-furyl methyl ketone (JECFA-no: 1503) (2-acetylfuran, [FL-no: 13.054]) available 
to the Committee at its present meeting were a study on UDS in cultured hepatocytes in vitro, a study 
on UDS in rat liver in vivo/in vitro and a test for SCEs in mouse bone marrow in vivo. 2-Furyl methyl 
ketone did not induce UDS either in vitro or in vivo/in vitro. However, it did induce SCEs, confirming 
the concern for clastogenicity as expressed by the Committee at its previous meeting. The Committee 
at its present meeting therefore considered that the new data available did not resolve the concerns 
expressed previously “. 
“The Committee concluded that the Procedure for the Safety Evaluation of Flavouring Agents could 
not be applied to this group because of the unresolved toxicological concerns. Studies that would 
assist in the safety evaluation include investigations of the influence of the nature and position of ring 
substitution on metabolism and on covalent binding to macromolecules. Depending on the findings, 
additional studies might include assays related to the mutagenic and carcinogenic potential of 
representative members of this group” 
At its 55th meeting (JECFA, 2001b) the JECFA has evaluated the substance 2-benzofuran 
carboxaldehyde [FL-no: 13.031] via the Procedure for the evaluation of flavouring substances. The 
JECFA conclude that the substance was of no safety concern. 
1.1.2. EFSA Considerations 
The group of furan derivatives evaluated by the JECFA is a very diverse group of 40 flavouring 
substances which can be subdivided into six major subgroups with further subdivision of subgroup V 
and VI, as depicted in the Table 1.1.2. The substance [FL-no: 13.031] has also been included in Table 
1.1.2. [FL-no: 13.031] was evaluated by the JECFA at the 55th meeting (JECFA, 2001b) in the group 
of furfuryl derivatives evaluated by EFSA in FGE.66Rev1, but as substance [FL-no: 13.031] has 
structural similarity to [FL-no: 13.074] considered in FGE.67, it will be included in the current  
revision of FGE.67. 
The structures of these 41 substances are given in Table 1.1.2.  
Table 1.1.2  Sub-grouping of 40 furan-substituted substances considered by JECFA at the 55th, 65th and 69th 
meetings  
Sub-
group* 
FL-no 
JECFA-no 
EU Register name Structural formula Supporting substances, 
represented in FGE and 
subgroup 
I 13.116 
1523 
2,5-Dimethyl-3-thioacetoxyfuran O
S
O FGE.65 
(Thioesters) 
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Table 1.1.2  Sub-grouping of 40 furan-substituted substances considered by JECFA at the 55th, 65th and 69th 
meetings  
Sub-
group* 
FL-no 
JECFA-no 
EU Register name Structural formula Supporting substances, 
represented in FGE and 
subgroup 
I 13.190 
1525 
3-((2-Methyl3-furyl)thio)-2-butanone O
S
O
FGE.13Rev2  
Subgroup Iia 
(Sulphides) 
I 13.191 
1526 
o-Ethyl S-(2-furylmethyl)thiocarbonate 
O
S O
O None in FGE.13Rev2, 
FGE.65 or FGE.66Rev1 
I 13.192* 
1524 
Furfuryl 2-methyl-3-furyldisulfide 
O
S
S
O FGE.13Rev2  
Subgroup Iic 
(Disulphides) 
II 13.006 
1517 
Phenethyl 2-furoate 
O
O
O FGE.13Rev2   
Subgroup Ia 
(Related to furfuryl alcohol) 
III 13.021 
1516 
Isopentyl 4-(2-furan)butyrate O O
O
FGE.13Rev2  
Subgroup Ia 
III 13.022 
1513 
Ethyl 3(2-furyl)propionate 
O
O
O FGE.13Rev2  
Subgroup Ia 
III 13.023 
1515 
Isopentyl 3-(2-furan)propionate 
O
O
O FGE.13Rev2  
Subgroup Ia 
III 13.024 
1514 
Isobutyl 3-(2-furyl)propionate 
O
O
O FGE.13Rev2  
Subgroup Ia 
III 13.047 
1518 
Propyl 3-(2-furyl)acrylate 
O
O
O FGE.13Rev2  
Subgroup Ia 
III 13.058 
1500 
3-(5-Methyl-2-furyl) butanal 
O
O
FGE.13Rev2  
Subgroup Ia 
IV 13.029 
1488 
2,5-Dimethylfuran O
 
FGE.13Rev2  
Subgroup Ic 
(Alkyl-substituted furans)  
IV 13.030 
1487 
2-Methylfuran O FGE.13Rev2  
Subgroup Ic 
IV 13.059 
1491 
2-Pentylfuran O FGE.13Rev2  
Subgroup Ic 
IV 13.069 
1492 
2-Heptylfuran O FGE.13rev2  
Subgroup Ic 
IV 13.092 
1489 
2-Ethylfuran O FGE.13rev2  
Subgroup Ic 
IV 13.103 
1490 
2-Butylfuran O FGE.13rev2  
Subgroup Ic 
IV 13.106 
1493 
2-Decylfuran O
 
FGE.13rev2  
Subgroup Ic 
IV 13.148 
1494 
3-Methyl-2(3-methylbut-2-enyl)furan 
O
FGE.13rev2  
Subgroup Ic 
V-A 13.052 
1520 
Furfuryl methyl ether O O None in FGE.13Rev2, 
FGE.65 or FGE.66Rev1 
V-A 13.061 
1522 
Difurfuryl ether 
O
O
O None in FGE.13Rev2, 
FGE.65 or FGE.66Rev1 
V-A 13.123 
1521 
Ethyl furfuryl ether O O None in FGE.13Rev2, 
FGE.65 or FGE.66Rev1 
V-B 13.031 
751 
2-Benzofurancarboxaldehyde OO None in FGE.13Rev2, 
FGE.65 or FGE.66Rev1 
V-B 13.074 
1495 
2,3-Dimethylbenzofuran 
O
None in FGE.13Rev2, 
FGE.65 or FGE.66Rev1 
V-C 13.107 
1496 
2,4-Difurfurylfuran OO
O
None in FGE.13Rev2, 
FGE.65 or FGE.66Rev1 
VI-A 13.034 
1497 
3-(2-Furyl)acrylaldehyde O
O
Not yet considered due to 
concern for genotoxicity. 
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Table 1.1.2  Sub-grouping of 40 furan-substituted substances considered by JECFA at the 55th, 65th and 69th 
meetings  
Sub-
group* 
FL-no 
JECFA-no 
EU Register name Structural formula Supporting substances, 
represented in FGE and 
subgroup 
VI-A 13.043 
1501 
Furfurylidene-2-butanal O
O
Not yet considered due to 
concern for genotoxicity. 
VI-A 13.044 
1511 
4-(2-Furyl)but-3-en-2-one 
O
O Not yet considered due to 
concern for genotoxicity. 
VI-A 13.046 
1498 
3-(2-Furyl)-2-methylprop-2-enal 
O
O Not yet considered due to 
concern for genotoxicity. 
VI-A 13.137 
1502 
3-(2-Furyl)-2-phenylprop-2-enal O O Not yet considered due to 
concern for genotoxicity. 
VI-A 13.150 
1499 
3-(5-Methyl-2-furyl)prop-2-enal O O Not yet considered due to 
concern for genotoxicity. 
VI-B 13.045 
1508 
1-(2-Furyl)-propan-2-one O
O  
FGE.13Rev2  
Subgroup Ib 
(Alkoyl-substituted furans) 
VI-B 13.054 
1503 
2-Acetylfuran 
O
O FGE.13Rev2  
Subgroup Ib 
VI-B 13.066 
1506 
3-Acetyl-2,5-dimethylfuran O
O
FGE.13Rev2  
Subgroup Ib 
VI-B 13.070 
1512 
2-Hexanoylfuran 
O
O FGE.13Rev2  
Subgroup Ib 
VI-B 13.083 
1504 
2-Acetyl-5-methylfuran 
O
O FGE.13Rev2  
Subgroup Ib 
VI-B 13.101 
1505 
2-Acetyl-3,5-dimethylfuran 
O
O FGE.13Rev2  
Subgroup Ib 
VI-B 13.105 
1507 
2-Butyrylfuran 
O
O FGE.13Rev2  
Subgroup Ib 
VI-B 13.138 
1510 
1-(2-Furyl)butan-3-one 
O
O FGE.13Rev2  
Subgroup Ib 
VI-B 13.163 
1509 
2-Pentanoylfuran 
O
O FGE.13Rev2  
Subgroup Ib 
VI-C 13.176 
1519 
Furaneyl butyrate O
O O
O
None in FGE.13Rev2, 
FGE.65 or FGE.66Rev1. 
* [FL-no: 13.192] is a synonym of substance [FL-no: 13.178] which has already been evaluated in FGE.13Rev2. 
 
Group I 
Four substances [FL-no: 13.116, 13.190, 13.191 and 13.192] are structurally related to 14 sulphur-
substituted furan derivatives evaluated by EFSA in FGE.13Rev2 (see Table 3.2) and 33 sulphur-
substituted furan derivatives considered by EFSA in FGE.65 (see Table 3.3). Substance [FL-no: 
13.192] appeared to be a synonym of substance [FL-no: 13.178] which has already been evaluated in 
FGE.13Rev2. Therefore this substance [FL-no: 13.192] will not be further considered in this FGE and 
should be removed from the Register. 
Group II 
One substance [FL-no: 13.006] is structurally related to five furoic acid esters considered by EFSA in 
FGE.66Rev1. 
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Group III 
Six substances [FL-no: 13.021, 13.022, 13.023, 13.024, 13.047 and 13.058] are structurally related to 
a group of furfuryl and furoic acid substances evaluated by EFSA in FGE.13Rev2 in subgroup Ia. 
Group IV 
Eight substances [FL-no: 13.029, 13.030, 13.059, 13.069, 13.092, 13.103, 13.106 and 13.148] are 
alkyl-substituted furans and structurally related to two substances evaluated by EFSA in FGE.13Rev2 
in subgroup Ic. In FGE.13Rev2 a concern for genotoxicity has been identified for structurally related 
substances. 
Group V 
The six substances in this group are not structurally related to any flavouring group evaluated or 
considered by EFSA. 
Subgroup V-A 
The three substances [FL-no: 13.052, 13.061 and 13.123] are furfuryl ethers. 
Subgroup V-B 
The two substances [FL-no: 13.031 and 13.074] are benzofuran derivatives. The substance [FL-no: 
13.031] has been evaluated for genotoxicity in FGE.19 subgroup 4.3 (EFSA, 2008b), and thereafter 
concluded to be of no concern with respect to genotoxicity based on structural considerations (EFSA, 
2011ac). 
Subgroup V-C 
The only substance [FL-no: 13.107] is a difurfurylfuran. 
Group VI 
Contains 16 alpha,beta-unsaturated carbonyls. These structures are considered by the Panel to be 
structural alerts for genotoxicity (EFSA, 2008b) and substances containing this structural characteristic 
have already been evaluated with respect to their genotoxic properties by EFSA in FGE.19 context 
(Subgroups 4.4b, 4.5 and 4.6 (EFSA, 2008b)). 
Subgroup VI-A 
Six substances (from FGE.19, subgroup 4.6, (EFSA, 2008b)) [FL-no: 13.034, 13.043, 13.044, 13.046, 
13.137 and 13.150] for which a need for additional information on genotoxicity was identified (EFSA, 
2008b). 
Subgroup VI-B 
This subgroup comprises nine substances. For seven substances in this subgroup (from FGE.19, 
subgroup 4.5, (EFSA, 2008b)) [FL-no: 13.054, 13.066, 13.070, 13.083, 13.101, 13.105 and 13.163] a 
need for additional information on genotoxicity was identified (EFSA, 2008b). After further 
considerations in the Panel it was concluded that these substances are comparable to acetophenone, an 
aromatic alpha,beta unsaturated ketone, which is not genotoxic. Therefore the alpha,beta-unsaturated 
ketone moiety in these seven furan derivatives is no longer considered to represent an alert for 
genotoxicity (EFSA, 2011ac); see also FGE.13Rev2). 
Subgroup VI-C 
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One substance (from FGE.19, subgroup 4.4b, (EFSA, 2008b)) [FL-no: 13.176] for which a need for 
additional information on genotoxicity was identified (EFSA, 2009ae). After further evaluation of 
additional data submitted by the Industry, [FL-no: 13.176] has been cleared for genotoxicity in 
FGE.220Rev1 (EFSA, 2011a). Because this substance has closely related structural analogues in 
FGE.75, and no structural analogues in FGE.67, this substance will be further considered in a revision 
of FGE.75 
Conclusion on subgroups 
Of the 40 substances in the JECFA group of furan derivatives (JECFA, 2006b) the following will not 
be dealt with in the present revision of FGE.67; six substances from subgroup VI-A (corresponding to 
FGE.19 subgroup 4.6) for which there still is a genotoxicity concern, one substance from subgroup 
VI-C [FL-no: 13.176] which has been transferred to FGE.75Rev1 for further consideration based on 
structural similarities and one substance from subgroup I [FL-no: 13.192] which is a duplicate of the 
substance [FL-no: 13.178] which has already been evaluated in FGE.13Rev2. In conclusion, in the 
present FGE.67Rev1, 33 substances will be evaluated. These comprise 32 of the 40 substances in the 
JECFA group of furan derivatives and one additional benzofuran also evaluated by the JECFA in the 
group of furfuryl derivatives (JECFA, 2001b). 
1.2. Isomers 
1.2.1. Status 
The following two substances [FL-no: 13.058 and 13.190] in the group of 33 JECFA evaluated furan-
substituted substances have a chiral centre and [FL-no: 13.047] has geometrical isomerism. 
1.2.2. EFSA Considerations 
Information is lacking about the stereoisomeric composition for [FL-no: 13.047]. 
1.3. Specifications 
1.3.1. Status 
The JECFA specifications are available for all 33 substances (JECFA, 2005d). See Table 1. 
1.3.2. EFSA Considerations 
The available specifications are considered adequate for 30 of the 33 JECFA-evaluated substances. 
Information on stereoisomeric composition is lacking for [FL-no: 13.047]. Information on solubility in 
water is missing for [FL-no: 13.045] and information on melting point is missing for [FL-no: 13.031], 
see Table 1. 
2. Intake Estimations 
2.1. Status 
For 31 of the 33 JECFA evaluated substances intake data are available for the EU, see Table 3.1. 
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2.2. EFSA Considerations 
Tonnage data for use as a flavouring substance in Europe are missing for two [FL-no: 13.066 and 
13.070] flavouring substances considered in this FGE.  
3. Genotoxicity Data 
3.1. Genotoxicity Studies – Text Taken4 from the JECFA (JECFA, 2009a) 
“Genotoxicity testing has been performed on eight [FL-no: 13.030, 13.029, 13.148, 13.034, 13.054  , 
13.044, 13.022 and 13.191) representative furan-substituted aliphatic hydrocarbons, alcohols, 
aldehydes, ketones, carboxylic acids and related esters, sulfides, disulfides and ethers in this group. 
The results of these tests are summarised in Table 2.1 (of this FGE), see (JECFA, 2009a), and 
described below”. 
In vitro 
“In standard Salmonella mutagenicity assays, 2,5-dimethylfuran [FL-no: 13.029], 3-methyl-2-(3-
methylbut-2-enyl)-furan [FL-no: 13.148], 3-(2-furyl)acrolein [FL-no: 13.034], 4-(2-furyl)-3-buten-2-
one [FL-no: 13.044], ethyl 3-(2-furyl)propanoate [FL-no: 13.022] and O-ethyl S-(2-furylmethyl)thio-
carbonate [FL-no: 13.191] were not mutagenic in Salmonella typhimurium strains TA97, TA98, 
TA100, TA102, TA1535, TA1537 or TA1538 when tested at concentrations of up to 10 000 μg/plate, 
alone or in the presence of an exogenous rat liver metabolic activation system (S9) (Wild et al., 1983; 
Mortelmans et al., 1986; Shinohara et al., 1986; Asquith, 1989a; Eder et al., 1991a; Zeiger et al., 1992; 
Lee et al., 1994a; Verspeek-Rip, 2000). Likewise, with the exception of a single assay in which 
equivocal results of mutagenicity were reported in S. typhimurium strains TA97 and TA107 (Zeiger et 
al., 1992) 2-methylfuran [FL-no: 13.030] was consistently negative in several other strains of S. 
typhimurium (i.e. TA98, TA100, TA102 and TA1535) both alone and with an exogenous rat liver 
bioactivation system (S9) (Shinohara et al., 1986; Aeschbacher et al., 1989). Evaluated alone and with 
an exogenous bioactivation system in S. typhimurium at concentrations of up to 0.660 μmol/plate (54.2 
μg/plate), 2-furyl methyl ketone [FL-no: 13.054] exhibited a significant positive mutagenic potential 
only in strain TA98 with bioactivation at the two lower concentrations (i.e. 0.165 and 0.330 
μmol/plate) (Shinohara et al., 1986). At higher concentrations, significant cytotoxicity was observed, 
which was reflected by a concentration-dependent decrease in the number of revertants. 
Bacterial mutagenicity testing of furans that can be metabolically oxidized to reactive alpha,beta-
unsaturated dicarbonyl (2-ene-1,4-dicarbonyl) intermediates is problematic owing to their high 
bacterial toxicity. The cytotoxicity of these substances is believed to arise from their interactions with 
protein sulfhydryl and amino groups (Marnett et al., 1985a; Eder et al., 1992). Owing to the nature of 
the GSH conjugation pathway, genotoxicity studies in which high concentrations of alpha,beta-
unsaturated carbonyl compounds are formed are likely to create oxidative stress. It is anticipated that 
cells exposed to high concentrations of these types of substances will rapidly deplete GSH levels, 
eventually leading to cellular damage and decreased cell viability, as indicated by the above study 
results. 
O-Ethyl S-(2-furylmethyl)thiocarbonate [FL-no: 13.191] showed no mutagenic potential when tested 
in Escherichia coli WP2uvrA at concentrations of up to 3330 μg/plate, either alone or with a 
bioactivation system (Verspeek-Rip, 2000). Evaluated in E. coli PQ37 under the conditions of the SOS 
chromotest, 3-(2-furyl)acrolein [FL-no: 13.034] tested negative (Eder et al., 1991); however, in a 
subsequent evaluation, 3-(2-furyl)acrolein [FL-no: 13.034]  as well as 2-furyl methyl ketone (2-
acetylfuran) [ FL-no: 13.054] were slightly positive in the SOS chromotest without metabolic 
activation, as evidenced by 1.72- and 1.75-fold increases, respectively, in the SOS induction factor 
                                                     
 
4 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
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over a background value of 1 (results were considered to be significant if the induction factor was at 
least 1.5) (Eder et al., 1993). 
In the rec assay, which is based on differential inhibition of growth of repair-deficient strains as a 
measure of DNA-damaging activity, Bacillus subtilis strains H17 (rec+) and M45 (rec-) were 
incubated with 2-methylfuran (FL-no: 13.030), 2,5-dimethylfuran (FL-no: 13.029) and 2-furyl methyl 
ketone [FL-no: 13.054] at concentrations of up to 55 000 μg/disc, alone and with metabolic activation 
(Shinohara et al., 1986). 2-Furyl methyl ketone tested negative at a concentration of 550 μg/disc, but 
was reportedly positive at concentrations of 5500 μg/disc and greater alone and with metabolic 
activation. Likewise, 2,5-dimethylfuran was negative at the lowest concentration tested (i.e. 190 
μg/disc) with metabolic activation, but tested positive at every concentration tested in the absence of 
metabolic activation. In contrast, 2-methylfuran was negative with metabolic activation and induced 
significant differences in the zones of inhibition only without metabolic activation. Additionally, 2-
methylfuran and 2-acetylfuran were reported to cleave the double strand of lambda-phage DNA in the 
presence of Cu2+; however, a negative control was not included, and, therefore, the statistical 
significance of these results was not ascertained. Also, it should be noted that potential concomitant 
cytotoxicity was not monitored in this study. 
The potential mammalian cell clastogenicities of 2-methylfuran (FL-no: 13.030), 2,5-dimethylfuran 
(FL-no: 13.029) and 2-furyl methyl ketone (FL-no: 13.054) were evaluated in Chinese hamster ovary 
(CHO) cells, in which induction of chromosomal aberrations was measured. Cells were exposed to 
substances from commercial sources (purity not given) for 3 hours, followed by 20 hours of 
maintenance. In the absence of exogenous metabolic activation, all three compounds produced 
increases in the number of chromosomal aberrations, mainly chromatid exchanges; however, in the 
presence of rat liver metabolic activation, only the clastogenicity of 2-furyl methyl ketone was 
increased, whereas the clastogenic activities of 2-methylfuran and 2,5-dimethylfuran were reduced in 
comparison with test systems without metabolic activation. Additionally, the authors noted that when 
NADP was eliminated from the activation system, the reduction in the chromosomal aberrations 
observed for 2-methylfuran and 2,5-dimethylfuran and the increase in the clastogenic activity 
observed with 2-furyl methyl ketone in the presence of the activation system were abolished. This 
suggests that mixed-function oxidases are integral in the metabolism of alkyl furan derivatives. It 
should be noted that the experiment with 2-furyl methyl ketone was performed at a limited number of 
concentrations (two), the active one of which far exceeded (112.6 mmol/l = 13 220 μg/ml) standard 
concentration limits for this assay and was toxic (Stich et al., 1981b). 
Beginning in the late 1980s, researchers began studying test conditions (osmolality, ionic strength, low 
pH) that could cause an increase in clastogenic activity (increased chromosomal aberrations and 
micronuclei) in the absence of any chemical-induced effect on DNA (Zajac-Kaye and Ts’o, 1984; 
Brusick, 1986; Bradley et al., 1987; Galloway et al., 1987a; Seeberg et al., 1988; Morita et al., 1989; 
Scott et al., 1991). More recent research indicates that extreme culture conditions (hypo- and 
hyperosmolality and high pH) induce apoptosis and necrosis, leading to DNA fragmentation and 
producing false-positive responses in clastogenic assays (Meintieres and Marzin, 2004). 
Apoptosis is a type of cell death that occurs under physiological conditions or in response to external 
stimuli (e.g. DNA-damaging agents, growth factor deprivation or receptor triggering). The mechanism 
of formation of apoptotic cells includes activation of cysteine proteases (caspases), leading to 
increased mitochondrial permeability, release of cytochrome c, DNA cleavage and redistribution of 
phosphatidylserine to the outer layers of the cell membrane, which enhances binding of cells to 
phagocytes. DNA cleavage, owing to irreversible activation of endonucleases, is followed by 
chromatin condensation and oligonucleosomal fragmentation due to double-strand cleavage of DNA 
in nucleosomal linker regions (Saraste and Pulkki, 2000). During chromatin condensation, the nucleus 
may split into a number of dense micronuclei. Fragmented DNA and chromatin condensation due to 
apoptotic events are not easily distinguished from direct action of a specific chemical. 
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In consideration of such knowledge, findings of chromosomal aberrations must be evaluated in the 
context of the potential for apoptosis to occur under test conditions. Relatively high concentrations 
(i.e. up to 1923 - 13 220 μg/ml or 20 - 150 mmol/l) were used in the study conducted by Stich et al. 
(Stich et al., 1981b). The Km for most enzyme kinetic processes is at or below 100 μmol/l (Bu, 2006; 
Wang and James, 2006), and thus the high concentrations used in this study may not be relevant to the 
human condition, especially with respect to the low levels of flavouring agents added to food. 
Furthermore, no information was available on culture conditions that may have promoted apoptosis. 
Results of chromosomal aberration and micronuclei assays are problematic to interpret in the absence 
of such information. 
2-Furyl methyl ketone (FL-no: 13.054) was evaluated for induction of unscheduled DNA synthesis 
(UDS) in human hepatocytes following OECD guidelines. Human (sex not given) hepatocytes from 
two batches purchased from a commercial provider were incubated with concentrations of compound 
(purity not given) of between 2.19 and 280 μg/ml for 16 hours, and UDS was measured 
autoradiographically. No UDS was elicited, in contrast to the positive control, 2-acetylaminofluorene 
(Durward, 2007a). 
In a study examining the effect of oxygen scavengers on cadmium chloride–induced chromosomal 
aberrations in Chinese hamster V79 cells, 2,5-dimethylfuran (FL-no: 13.029) at 96.13 μg/ml (1 
mmol/l) did not increase the frequency of chromosomal aberrations in comparison with control values. 
When 2,5-dimethylfuran at 96.13 μg/ml (1 mmol/l) was incubated with the V79 cells in the presence 
of cadmium chloride, no reduction in the clastogenic capacity of cadmium chloride was observed 
(Ochi and Ohsawa, 1985). 
O-Ethyl-S-(2-furylmethyl)thiocarbonate [FL-no: 13.191] was evaluated for potential clastogenicity in 
a series of tests in human peripheral lymphocytes. Doses at which chromosomal aberrations were 
evaluated were based on a preliminary evaluation of effects on the mitotic index in the cells. 
Generally, O-ethyl-S-(2-furylmethyl)thiocarbonate exhibited marked mitogenicity and cytotoxicity, 
and accordingly only a relatively narrow range of concentrations was used. In the first set of tests in 
which an exposure time of 3 hours was utilized, the substance did not induce an increase at 
concentrations ranging between 150 and 350 μg/ml alone or in the presence of a bioactivation system; 
however, in another test employing a 3-hour exposure period with metabolic activation, significant 
and dose-dependent increases in the number of chromosomal aberrations were observed at 
concentrations of 325 and 375 μg/ml, but not at 150 μg/ml. Moreover, following a 24- or 48-hour 
exposure period, O-ethyl-S-(2-furylmethyl)thiocarbonate (up to 280 μg/ml) also induced dose-
dependent and statistically significant increases in the number of chromosomal aberrations in the 
absence of metabolic activation in comparison with a negative control (Meerts, 2000). 
In vivo 
As reported in an abstract, 2-methylfuran [FL-no: 13.030] (purity not given) did not induce 
chromosomal aberrations in bone marrow cells or spermatocytes of Swiss albino mice evaluated at 24-
hour intervals following administration in the diet at concentrations of 1000, 2000 or 4000 mg/kg 
(approximately 100, 200 and 400 mg/kg bw per day, respectively) for a period of 5 days. No positive 
control was included. Moreover, the authors noted that 2-methylfuran did not inhibit spindle protein 
synthesis or cell division in the somatic cells. In the germ cells, which were evaluated at weekly 
intervals for a period of 5 weeks following final dosing, in order to cover one full spermatogenesis 
cycle, no structural sperm-head abnormalities were reported (Subramanyam et al., 1989). 
2-Furyl methyl ketone [FL-no: 13.054] was evaluated for clastogenic activity in bone marrow and 
germ cells of Swiss albino mice. Groups of two per dose per sampling time were administered the 
compound (99 % pure) orally at 0 (control), 1000, 2000 or 3000 mg/l in 0.5 ml of water 
(approximately 0, 20, 40 and 60 mg/kg bw, respectively) either as a single dose or once daily for 5 
consecutive days. No positive control was included. Bone marrow cells were collected periodically for 
up to 72 hours following dosing, and meiotic and sperm preparations from testes and epididymis, 
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respectively, were assessed at 24 hours and weekly for a total of 5 weeks post-dosing. In bone marrow 
cells, the substance at the high dose level was observed to inhibit mitosis beginning at 18 hours 
following single- or multiple-dose treatment. At 24 hours, mitodepression was also observed at the 
high dose level in the single-dose experiment, as well as at the middle and high dose levels in mice 
administered multiple doses. In the repeat-dose test protocol, the effect remained significant for up to 
36 hours post-treatment. Mitodepression was accompanied by increases in the frequency of structural 
chromosomal aberrations, mainly gaps and breaks, in the bone marrow cells. Specifically, at the high 
dose level (i.e. 3000 mg/l), between 18 and 24 hours following single-dose administration and 12 and 
48 hours following final treatment of multiple-dose groups, the frequency of aberrations was elevated. 
Additionally, in animals receiving multiple doses of 2-furyl methyl ketone, significant increases in the 
number of chromosomal aberrations were also observed at the middle dose level (i.e. 2000 mg/l) 
between 24 and 36 hours post-treatment. In contrast to the dose- and time-dependent increase in 
chromosomal aberrations in the somatic cells, only a single isolated increase in structural 
chromosomal aberrations was observed in mouse spermatocytes 3 weeks following single-dose 
administrations of the substance, and only at the highest dose level. Following multiple-dose 
administration, abnormalities in germ cells were limited to significant increases in polyploidy and XY 
univalents occurring at weeks 3 and 4 at the highest dose level. Furthermore, no sperm-head 
abnormalities were observed at any dose level, irrespective of the treatment protocol. The absence of 
sperm-head abnormalities at all dose levels was indicative of a lack of sperm toxicity of the substance. 
The authors concluded that 2-furyl methyl ketone exhibits only mild clastogenic activity in mouse 
bone marrow and is not clastogenic in germ cells (Sujatha et al., 1993). 
2-Furyl methyl ketone was evaluated for induction of sister chromatid exchanges (SCE) in bone 
marrow of female Swiss albino mice. Groups of two per dose per exposure regimen were administered 
compound (99 % pure) at 0, 1000, 2000 or 3000 mg/l via gavage either once or for 5 consecutive days. 
5- Bromodeoxyuridine was injected intraperitoneally to label chromatids. The mice were sacrificed at 
12, 24 or 48 hours after receiving the last dose, and slides of bone marrow were prepared and 
processed for differential staining. A dose-related increase up to about 2-fold in SCE was observed for 
the 12- and 24-hours groups of both the single-dose regimen and the multiple-dose regimen (Sujatha, 
2007). 
2-Furyl methyl ketone was evaluated for induction of UDS in hepatocytes isolated from livers of 
dosed male Sprague-Dawley rats. The assay was conducted according to Good Laboratory Practices 
and OECD guidelines. In a preliminary range-finding toxicity study, lethality was observed at 30 
mg/kg bw and greater, and signs of toxicity were observed at 20 mg/kg bw. No sex differences were 
observed, and therefore only males were used in the main study. Groups of four rats were administered 
compound (purity not given) at 0, 7 or 21 mg/kg bw via gavage. In experiment 1, the hepatocytes were 
isolated 16 hours post-dosing; in experiment 2, hepatocytes were isolated 2 hours post-dosing and 
cultured for autoradiographic measurement of UDS. No UDS was observed in either experiment, in 
contrast to the positive controls 2-acetylaminofluorene and N,N’-dimethylhydrazine (Durward, 
2007b). 
O-Ethyl S-(2-furylmethyl)thiocarbonate (FL-no: 13.191) was evaluated for induction of micronuclei in 
bone marrow erythrocytes of NMRI BR mice. Groups of five per sex per dose per sampling time were 
administered single doses of compound (99 % pure) at 0 (vehicle control), 100, 250 or 500 mg/kg bw 
in corn oil via gavage. Dosed animals at every dose level and controls were killed at 24 hours 
postdosing. Additionally, a second group of high-dose mice (i.e. 500 mg/kg bw) and the positive 
control (cyclophosphamide) group were terminated at 48 hours post-dosing. Bone marrow smears 
were prepared from the femurs. No increase in the incidence of micronucleated polychromatic 
erythrocytes was observed in dosed mice compared with controls, in contrast to the positive control, 
which induced a 20-fold increase. However, the authors also noted that cells obtained from dosed 
animals did not exhibit a reduction in the ratio of polychromatic to normochromatic erythrocytes, 
indicating an absence of toxicity, which could be due to lack of adequate exposure of bone marrow 
(Verspeek-Rip, 2001)”. 
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Conclusions on genotoxicity 
“With few exceptions, eight representative substances of this group were consistently negative in 
mutation assays conducted in various strains of S. typhimurium and E. coli under appropriate testing 
conditions. Negative and positive results were obtained in the rec assay in B. subtilis for 2-methylfuran 
and 2,5-dimethylfuran. In mammalian genotoxicity assays conducted in CHO and V79 cells and 
human peripheral lymphocytes, study results were inconsistent, with both negative (2,5-dimethylfuran, 
O-ethyl-S-(2-furylmethyl)thiocarbonate) and positive (2-methylfuran, 2,5-dimethylfuran) results 
reported. Although positive results were reported in the chromosomal aberration assay in CHO cells 
with 2-methylfuran and 2,5-dimethylfuran, relatively high concentrations were utilized (i.e. up to 
13220 and 1923 μg/ml, respectively); the statistical significance of the results was not specified, and 
the potential cytotoxicity was not monitored in the assay. Moreover, as previously discussed, positive 
in vitro results of chromosomal aberrations are difficult to interpret in the presence of concomitant 
cytotoxicity and cell cycle delay, which, based on the results of the studies, are a feature of the furan 
derivatives. Therefore, it may be expected that mammalian cells in culture might not have adequate 
metabolic capacities to counter this toxicity. In fact, with the exception of one assay in which 
clastogenic activity was reported for a single compound (i.e. 2-furyl methyl ketone) with a metabolic 
activation system, results obtained with other representative furan derivatives demonstrated a 
reduction in the frequency of chromosomal aberrations in the presence of metabolic activation. 
Furthermore, unlike the positive results reported for 2,5-dimethylfuran among several other 
compounds evaluated in CHO cells at the high concentrations used in the study of Stich et al. (Stich et 
al., 1981b) 2,5-dimethylfuran, tested at lower concentrations in V79 cells, did not exhibit clastogenic 
activity (Ochi and Ohsawa, 1985). The negative findings in the human hepatocyte DNA damage assay 
provide evidence that the chromosomal aberration findings are not due to a DNA-reactive mechanism. 
Three representative compounds were studied in in vivo assays. With 2-methylfuran, no increase in 
chromosomal aberrations was found in either mouse bone marrow cells or spermatocytes. In a study in 
which mild clastogenic activity was reported in mouse bone marrow cells at the middle and high doses 
of 2-furyl methyl ketone (i.e. 40 and 60 mg/kg bw, respectively), at which the authors also reported 
significant mitodepression following single- and multiple dose administrations, no increase in 
chromosomal aberrations was observed in the spermatocytes obtained from the same mice, and the 
weak clastogenic effects achieved statistical significance only after repeated daily exposure to near-
lethal doses. A study from the same laboratory reported induction of SCEs in mouse bone marrow 
cells by 2-furyl methyl ketone. However, 2-furyl methyl ketone did not elicit UDS in hepatocytes 
isolated from rat liver, suggesting that any possible in vivo genotoxicity is not attributable to DNA 
reactivity. The frequency of micronucleus formation in bone marrow cells of mice administered single 
doses of O-ethyl-S-(2-furylmethyl)thiocarbonate was comparable with control values (Verspeek-Rip, 
2001), although adequacy of exposure was not demonstrated. 
In conclusion, results of the in vitro genotoxicity/mutagenicity tests revealed mixed results, with 
positive results reported less frequently in the presence of an activation system. This could indicate 
metabolic detoxication of these substances. The in vivo single-dose studies with 2-furyl methyl ketone 
did not indicate evidence for genotoxicity, whereas two repeat-dose studies showed weak effects for 
induction of chromosomal aberrations and SCEs. However, evidence indicates that 2-furyl methyl 
ketone does not exhibit DNA reactivity. The basis for the positive clastogenicity findings remains 
unclear. 
For a summary of in vitro / in vivo genotoxicity data considered by the JECFA, see Table 2.1. 
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3.2. Genotoxicity Studies – Text taken5 from the JECFA (JECFA, 2001b) 
The JECFA did not provide a text on the genotoxicity in their evaluation of the group of furfuryl 
alcohol and related substances including flavouring substance [FL-no: 13.031]. The JECFA only 
presented the study results in table format. 
For a summary of in vitro / in vivo genotoxicity data considered by the JECFA see Table 2.5. 
3.3. Genotoxicity Studies - Text taken6  from EFSA FGE.13Rev2 (EFSA, 2011h) 
In the following text, which is taken from FGE.13Rev2, the FGE.13-(sub)grouping is maintained. 
Genotoxicity studies were available only on some of the candidate substances included in main group 
I or on their related supporting substances. For subgroup Ia, data on in vitro genotoxicity were 
provided for the two candidate substances 5HMF [FL-no: 13.139] and furoic acid [FL-no: 13.136] as 
well as for five supporting substances. Data on in vivo genotoxicity were only provided on two of the 
supporting substances from subgroup Ia. New genotoxicity data on the candidate substance 5HMF 
have become available and will be considered in this revision of FGE.13. 
For the one candidate substance [FL-no: 13.155] min subgroup Ib no genotoxicity data are available, 
but in vitro and in vivo genotoxicity data are available for the supporting substance acetylfuran [FL no: 
13.054]. 
For subgroup Ic, data on in vitro genotoxicity were provided for two supporting substances. Data on in 
vivo genotoxicity were only provided for one of the two supporting substances [FL-no: 13.029 and 
13.030]. Since the supporting substance for subgroup Ib gives information on genotoxic properties of 
putative metabolites of the candidate substances in subgroup Ic, the information given for the 
evaluation of subgroup Ib is also relevant for subgroup Ic. 
No genotoxicity data were available on candidate- or on structurally related substances in main group 
II (i.e. furans with sulphur-containing ring substituents). 
Subgroup Ia 
Candidate substances: 
5-hydroxymethyl furfural [FL-no: 13.139] 
In the in vitro tests, 5HMF gave negative results in the traditional Ames test in strains TA98, TA100, 
TA104, TA1535 and TA1537 in five and positive results in two studies. The validity of these two 
studies could not be assessed. In one of these two studies (Omura et al., 1983) the positive response 
was observed in strain TA100, but not in TA98 and the mutagenic potential was higher in the absence 
of S9 than in the presence of S9. In the other study (Shinohara et al., 1986) mutagenicity was only 
observed in strain TA100 in the presence of metabolic activation (see Table IV.4). A positive result 
was obtained also in the Umu assay, although only at high concentrations, resulting in reduced cell 
viability (Janzowski et al., 2000) and in a Rec assay on B. subtilis (Shinohara et al., 1986). In V79 
cells, 5HMF induced a small (although statistically significant) increase in chromosomal aberrations, a 
reduction in mitotic index and, only at high concentrations, resulting in reduced cell viability, also 
HPRT mutations (Janzowski et al., 2000). In TK6 human lymphoblast cells, 5HMF gave negative 
results in the HPRT and TK assay (Surh and Tannenbaum, 1994) 
                                                     
 
5 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
6 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed. 
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In an Ames test with TA 104 strain upon inclusion of PAPS, a sulpho-group donor, and rat liver 
cytosol into the experimental model, 5HMF gave a positive result, suggesting that it can be activated 
to reactive metabolites following sulphation, with formation of sulphate-ester (SMF). Indeed, the 
mutagenic effect could be partly suppressed by the addition of sulphotransferase inhibitors. In 
accordance, SMF in TA104 was genotoxic in the absence of any metabolic system (cytotoxicity not 
specified); the effect was reduced by addition of glutathione (GSH) and GSH-transferases and restored 
when this latter enzyme was inhibited (Lee et al., 1995b).  
The formation of SMF was supported by the detection of an unstable conjugate, which disappeared 
within 60 minutes, when 5HMF was incubated with 35S-PAPS and liver cytosol. The exact nature of 
SMF was not elucidated, but its molecular mass was consistent with that of the sulphate-ester of 
5HMF (Surh and Tannenbaum, 1994). 
When the genotoxicity of chemically synthesised SMF was tested in Salmonella strain TM677 (8-AG-
resistance), without any metabolic activation, a clear positive response was obtained at concentrations 
that reduced cell survival to < 60 %. Genotoxicity was also observed with SMF in human 
lymphoblasts at the TK and HPRT loci, at concentrations (> 40 microg/ml) reducing cell survival to > 
63 %. No genotoxicity was observed with 5HMF, with its acetate ester or with the sulphation product 
of 2-methyl furfuryl alcohol, suggesting that the genotoxicity of SMF requires the presence of both a 
reactive sulphate group and a free aldehyde group. 
An assay for primary DNA damage (“Comet assay”) did not show an effect of 5HMF in V79 and 
Caco-2 cells up to cytotoxic concentrations (80 mM). 5HMF causes a slight but significant increase in 
DNA single strand breaks in primary rat hepatocytes at cytotoxic levels (40 - 100 mM), whereas in 
human colon biopsy material the same effect was seen in the absence of cytotoxicity. 5HMF at non 
cytotoxic concentrations induced a substantial concentration-related GSH depletion in V79, Caco-2 
and rat liver cells. The effect of sulphate conjugation was not directly studied, but since this activity is 
present at least in primary hepatocytes, it might have contributed to the depletion of GSH and to 
induction of DNA strand breaks in these cells. However, this study was not considered appropriate to 
evaluate the possible mutagenic activity of SMF in mammalian cells and consequently of 5HMF in 
vivo (Janzowski et al., 2000). 
To support the genotoxic potential of 5HMF, some indications for tumorigenic activities of 5HMF 
have been obtained with rats and mice. It has been reported that 5HMF may act as both an initiator and 
a promoter in the induction of colonic aberrant cryptic foci in rats (Archer et al., 1992; Bruce et al., 
1993; Zang et al., 1993). In addition induction of skin papillomas has been described after topical 
application of doses of 10 or 25 micromol 5HMF to mice (Surh et al., 1994). 
Newly submitted data on 5-hydroxymethylfurfural7(Included in Table 2.2 and 2.3 of this FGE) 
Weak mutagenic activity was reported in S. typhimurium TA100 strain in the absence of metabolic 
activation, while no mutagenicity was observed in strains TA97, TA98, TA102 and TA1535 in a range 
of concentrations of 100 - 10,000 micrograms/plate; however, negative results were reported in 
another study with TA98 and TA100 strains and E. coli WP2 uvrA/pKM101 in a range of 
concentrations of 1,500 - 10,000 micrograms/plate (NTP, 2010c). 
At the end of a 3-month toxicity study, peripheral blood samples were obtained from male and female 
B6C3F1 mice receiving 0, 47, 188, 375 or 750 mg/kg bw/day of 5HMF via gavage. Slides were 
scanned to determine the frequency of micronuclei in 1,000 normochromatic erythrocytes (NCEs) in 
10 animals per sex per treatment group. In addition, the percentage of polychromatic erythrocytes 
                                                     
 
7 An in vivo micronucleus test in mouse bone marrow with neofuraneol was also submitted, but an adequate identification of 
the substance studied was not possible due to incomplete reporting. The study did not show an effect of neofuraneol on the 
occurrence of micronuclei. Since no target organ toxicity was seen, this evidence provided by this study is of very limited 
relevance. For these two reasons the study is not further discussed. 
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(PCE) in a population of 1,000 erythrocytes was determined as a measure of bone marrow toxicity. No 
increases in the frequency of micronucleated erythrocytes were observed; in addition, no significant 
dose-related changes in the percentage of immature PCE were observed, suggesting that the chemical 
did not exhibit bone marrow toxicity (NTP, 2010c). 
The DNA-damaging potential of 5HMF was tested in vitro in the Comet assay with the following five 
cell lines with various degree of SULT1A1 expression (Durling et al., 2009): two human lines (Caco-
2, no detectable 1A1 activity; HEK293, high 1A1 activity); two cell lines from Chinese hamster (V79, 
no detectable 1A1 activity and V79-hp-PST, high 1A1 activity) and a one mouse lymphoma line 
(L5178Y, no detectable activity). The cell lines were incubated with 0, 2.5, 7.5, 25, 50 or 100 mM (ca. 
0, 0.3, 1.0, 3.3 6.3 or 12.6 mg/ml) of 5HMF for three hours and subjected to a Comet assay to study 
DNA damage. 
DNA damage was observed at the highest concentration (100 mM) in all cell lines, with significant 
reduction in cell viability (from 11 to 30 %), The concentration of 100 mM is ten times higher than the 
highest concentration (10 mM or 5000 micrograms/ml) recommended by OECD guidelines for in vitro 
testing with mammalian cells. 100 mM was the lowest effective concentration for three cell lines: 
Caco-2, HEK293 and L5178Y. In the V79 (lowest SULT1A1) and V79-hp-PST (highest SULT1A1) 
DNA damage was induced also at lower concentrations (lowest effective concentration: 25 mM or 
3193 micrograms/ml), without a reduction in cell viability. Surprisingly, the positive control (HMP, 
0.01 mM) induced significant damage in Caco-2, V79 and V79-hp-PST cells, but not in HEK293. The 
authors (Durling et al., 2009) concluded that 5HMF DNA damage in all cell lines was unrelated to the 
expression of SULT1A1 but they mentioned that the SULT1A1 activities in these three cell lines 
(Caco-2, HEK293 and L5178Y) were much lower than those that can be found in human gut and liver. 
The possibility was left open that SULT1A1 activity was too low to efficiently bioactivate 5HMF also 
in the cell line with highest SULT1A1 activity. In V79 cells without SULT1A1 activity and in V79-
hp-PST with SULT1A1 activity at the same level as in human gut and liver, no difference in extent of 
DNA-damage could be observed. This would indicate absence of a significant contribution of sulphate 
conjugation in the DNA-damaging activity of 5HMF.  
These results are in conflict with the results of Glatt et al. (Glatt et al., 2005) who reported induction of 
SCE in 5HMF-exposed genetically modified V79 cells expressing high levels of human CYP2E1 and 
SULT1A1. They are also in conflict with the observations by Sommer et al. (Sommer et al., 2003) 
reporting the mutagenicity of 5HMF in a S. typhimurium strain genetically modified and expressing 
human SULT1A1. According to Durling et al. (2009), the reasons of these discrepancies are unknown; 
one possibility is the different sensitivity of the Comet assay compared to other systems. Durling et al. 
(Durling et al., 2009) concluded that other important mechanisms for the observed DNA damage 
should be investigated, but that under the conditions of the test, 5HMF is a rather weak DNA-
damaging agent. 
In a new publication by Severin et al. (2010), a dose dependent increase in DNA damage was 
observed in a Comet assay with HepG2 cells exposed to 5HMF (0, 5.35, 7.87, 11.57, 17, 25, 36.6 
mM) for 20 hours, with a significant increase from 7.87 to 36.6 mM 5HMF. Cytotoxicity was 
observed at the two highest doses (25 and 36.6 mM), with estimated IC50 of 38 mM. HepG2 cells 
express both CYP and SULT enzymes. In the same publication no effect of 5HMF was found in an in 
vitro micronucleous assay in the same cell line exposed to similar doses of 5HMF (20 hours). 5HMF 
was also tested in an Ames test performed according to the OECD guidelines 471. No increase in 
mutants was observed in S. typhimurium strains TA98, TA100, TA1535 and TA1537 exposed to 
5HMF at 0.5 µg/mL up to 5000 µg/mL with or without metabolic activation (S9). However, no 
additional PAPS was added to the test system (Severin et al., 2010).  
However, while 5HMF was unable to induce micronuclei in vivo, in the NTP 3-months study in mice 
by gavage, and in vitro, using the Hep-G2 human cell line expressing both CYP and SULT enzymes, 
its metabolite SMF has been reported to induce micronuclei in peripheral erythrocytes in mice 
(Dahlberg, 2004) as cited by Glatt and Sommer, 2006 (no further data were available)). 
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According to Glatt and Sommer (2006), incubation of DNA with SMF in a cell-free system led to the 
formation of DNA adducts that could be detected by the 32P-postlabelling technique. No adducts were 
formed in incubations with 5HMF instead of SMF. In subsequent experiments, the authors searched 
for these adducts in mammalian and bacterial cells treated with SMF and in SULT-proficient cells 
treated with 5HMF. Although mutations were induced, adducts were not seen in these cells under the 
same conditions (no data are available to be listed in the genotoxicity table). The authors hypothesized 
that the lack of DNA adducts might be due to technical problems, since generally DNA adducts are a 
more sensitive endpoint than mutations as observed with many other compounds (Glatt and Sommer, 
2006). 
In conclusion, with respect to the genotoxicity 5HMF, taking into account additional data on 
metabolism, the following picture emerges. The substance is negative in the conventional Ames test. 
Mutagenicity is observed only upon inclusion of PAPS, a sulpho-group donor and liver cytosol into 
the metabolic system, suggesting the formation of a sulphate-ester (SMF). In accordance, SMF was 
mutagenic in the absence of any metabolic activation system. In an in vitro assay, 5HMF induced 
dose-dependent increase in DNA damage (Comet assay), but this study has major drawbacks and 
inconsistencies and has to be considered of limited validity. A major limitation is the use of too high 
concentrations that can produce unpredictable effects, not related to the real genotoxic potential of 
5HMF, and this is particularly true for a test like the Comet assay. Furthermore, as also stated by the 
authors, DNA damage was unrelated to the expression of SULT1A1 activity. Also in another Comet 
assay in HepG2 cells, able to express both CYP and SULT enzymes, indications for DNA damage 
were observed, but the substance did not induce clastogenic or aneugenic effects (micronucleus assay) 
in the same cell system. In vivo, a non-standard micronucleus assay in peripheral blood erythrocytes 
associated to a sub-chronic study in mice, provided no indication of a genotoxic potential, but this 
study has limited validity since no bone marrow cell toxicity was observed. 
Metabolic studies indicate that in vivo, in mice B6C3F1 and rats, the principal route of metabolism is 
oxidation of 5HFM to 5-hydroxymethylfuroic acid, followed by glycine conjugation and rapid 
elimination in the urine. However, a recent pharmacokinetic study in FVB/N mice has shown that 
SMF has been detected in plasma from animals given 5HMF, intravenously. This indicates that there 
is a competition for the substrate 5HMF between the oxidation pathway leading to furoic acid 
derivative and the sulphonation pathway leading to the SMF metabolite. The Panel noted that SMF is 
very hydrophilic and therefore will have problems crossing the cell membrane and entering cells. 
Therefore SMF is more likely to induce mutation at the site of formation, mainly the liver. In addition, 
the half life was reported to be 4.2 minutes, and it is not likely that this metabolite will manage to 
reach the bone marrow and give any positive effect in an in vivo  micronucleus test, taking into 
account that SMF will most likely be formed in the liver. However, 5HMF has been found unable to 
induce micronuclei also in vitro, using the HepG2 human cell line, expressing both CYP and SULT 
enzymes. In the rodent bioassays no carcinogenic response was observed and from this it may be 
concluded that the formation of the SMF metabolite is too low to result in a carcinogenic response. 
Assuming that in humans the ratio between the two competing pathways is not more favourable for the 
formation of SMF than in rodents, no genotoxicity or carcinogenicity is expected in humans either. 
Furoic acid [FL-no: 13.136] 
Furoic acid gave negative results in three studies in the Ames test in strains TA 98 and TA 100. Furoic 
acid was also negative in DNA repair test in E.coli and in a UDS assay using primary rat hepatocytes. 
Supporting substances 
In vitro genotoxicity data were available for five supporting substances: furfuryl acetate, furfuryl 
alcohol, furfural, 5-methylfurfural and methyl-2-furoate [FL-no:  13.128, 13.019, 13.018, 13.001 and 
13.002] and in vivo genotoxicity data for the two supporting substances furfuryl alcohol and furfural 
[FL-no: 13.019 and 13.018]. Most studies were negative, although some positive results were reported.  
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However, the genotoxicity of furfural has recently been re-evaluated by the AFC panel, which 
concluded that furfural did not induce gene mutations in vivo, on the basis of new studies with 
transgenic mice (EFSA, 2004c). 
Overall, the genotoxicity data available on the candidate furoic acid and on supporting substances do 
not give rise to concern with respect to genotoxicity of nine candidate furfural-related candidate 
substances included in subgroup Ia [FL-no: 13.011, 13.102, 13.122, 13.127, 13.129, 13.130, 13.132, 
13.133 and 13.136]. Based on newly submitted data on the mutagenic activity of 5HMF [FL-no: 
13.139] the concern for genotoxicity which was raised because of genotoxic properties of one of its 
metabolites (SMF) is overcome. Thus there are no further concerns for genotoxicity of the candidate 
substances in subgroup Ia, which could preclude their evaluation through the Procedure. 
Subgroup Ib 
No data are available for the one candidate substance in subgroup Ib ([FL no: 13.155]). However, 
several studies have been carried out with a structurally related flavouring substance, 2-acetylfuran 
[FL-no: 13.054] (2-furyl methyl ketone).  
In vitro studies 
For the supporting substance 2-acetylfuran [FL-no: 13.054] data were found showing an increased 
mutation frequency in a bacterial reverse gene mutation test in S. typhimurium TA98 with metabolic 
activation, but not in TA100. The study has limited validity. The increase was not dose-related and no 
clear data on cytotoxicity were presented, but a decrease in the number of revertants was observed at 
the highest concentrations, which could indicate cytotoxicity. A second trial was not performed 
(Shinohara et al., 1986). Also with this substance a positive result was obtained in the rec-assay 
(Shinohara et al., 1986) and in an SOS-chromo test for bacterial DNA-repair (Eder et al., 1993), but 
the predictive value of these test systems is considered to be limited. With [FL-no: 13.054] also 
chromosomal aberrations in Chinese hamster ovary cells have been reported in a limited study by 
Stich et al. (Stich et al., 1981b). 
2-Acetylfuran [FL-no: 13.054] was evaluated for induction of unscheduled DNA synthesis (UDS) in 
human hepatocytes following OECD guidelines. Human (gender not given) hepatocytes from two 
batches purchased from a commercial provider were incubated with concentrations of the compound 
(purity not given) between 2.19 and 280 μg/ml for 16 hours, and UDS was measured 
autoradiographically. No UDS was elicited, in contrast to the positive control, 2-acetylaminofluorene 
(Durward, 2007a) 
In vivo studies 
2-Acetylfuran [FL-no: 13.054] was also evaluated for induction of sister chromatid exchanges (SCE) 
in bone marrow of female Swiss albino mice. Groups of two per dose per exposure regimen were 
administered compound (99 % pure) at 0, 1000, 2000 or 3000 mg/l via gavage either once or for 5 
consecutive days. 5-Bromodeoxyuridine was injected intraperitoneally to label chromatids. The mice 
were sacrificed at 12, 24 or 48 hours after receiving the last dose, and slides of bone marrow were 
prepared and processed for differential staining. A dose-related increase up to about 2-fold in SCE was 
observed for the 12- and 24-hour groups of both the single-dose regimen and the multiple-dose 
regimen (Sujatha, 2007). This study was considered valid. In an earlier study by the same group 
(Sujatha et al., 1993) this substance was reported to cause chromosomal aberrations in mouse bone 
marrow at oral dose levels up to 60 mg/kg bw/day. Also this study was considered valid. 
2-Acetylfuran was evaluated for induction of UDS in hepatocytes isolated from livers of dosed male 
Sprague-Dawley rats. The assay was conducted according to GLP and OECD guidelines. In a 
preliminary range-finding toxicity study, lethality was observed at 30 mg/kg bw and greater, and signs 
of toxicity were observed at 20 mg/kg bw. No sex differences were observed, and therefore only males 
were used in the main study. Groups of four rats were administered test compound (purity not given) 
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at 0, 7 or 21 mg/kg bw via gavage. In experiment 1, the hepatocytes were isolated 16 hours post-
dosing; in experiment 2, hepatocytes were isolated 2 hours post-dosing and cultured for 
autoradiographic measurement of UDS. No UDS was observed in either experiment (Durward, 
2007b). 
The candidate and supporting substance in this subgroup are alpha,beta-unsaturated ketones. This 
structural characteristic has been considered as an additional reason for concern for genotoxic 
potential of these substances. However, due to structural similarity with acetophenone (i.e. the 
alpha,beta unsaturated double bond is part of an aromatic system and therefore less reactive) the 
concern for genotoxicity, resulting from the formation of such alpha,beta-unsaturated ketones has been 
lifted (EFSA, 2011ac). Nevertheless, the experimentally obtained genotoxicity data indicate that the 
supporting substance may give rise to DNA damage, which may result in chromosomal aberrations 
rather than gene mutations. Also from Chapter 4 and Annex III (FGE.13Rev2 (EFSA, 2011h), the 
formation of DNA-reactive metabolites may be anticipated. In combination with this, the available 
genotoxicity data are sufficiently strong to raise a concern, which would preclude the evaluation of the 
candidate substance in subgroup Ib through the Procedure. 
Subgroup Ic 
No data are available on the genotoxic properties of the two candidate substances in this subgroup. 
Several studies were found with the supporting substances 2-methylfuran [FL-no: 13.030] and 2,5-
dimethylfuran [FL-no: 13.029]. Negative results were obtained in a limited bacterial reverse gene 
mutation test with S. Typhimurium (TA97 and TA100 strains only, no data on cytotoxicity, no 
duplicate trial; (Shinohara et al., 1986)). However, a clear dose-related positive response with limited 
validity (e.g. no clear data on cytotoxicity; no clear description of scoring criteria) was obtained with 
both substances in a chromosome aberration test in Chinese hamster ovary cells with and without 
metabolic activation in presence or absence of metabolic activation (Stich et al., 1981b). Both 
substances also gave a positive response in a rec-assay for bacterial DNA-repair (Shinohara et al., 
1986), but the predictive value of this test system is considered to be limited. With 2-methylfuran an 
equivocal result was obtained in a bacterial reverse gene mutation assay with S. typhimurium in strain 
TA97. This test was considered valid (Zeiger et al., 1992). 
For a 2-alkyl- and 2,5-dialkyl-substituted furans, formation of reactive intermediates cannot be 
excluded (see Chapter 4 and Annex III, FGE.13Rev2 (EFSA, 2011h). These reactive intermediates can 
bind covalently to DNA, which might result in genotoxic events. In an alternative metabolic pathway, 
these flavouring substances may also be converted to ketones which are structurally related to the 
substances in subgroup Ib and for these substances a concern for genotoxicity has been identified. 
Therefore, owing to the anticipated metabolism of the two candidate substances in subgroup Ic into 
possible genotoxic metabolites a concern for genotoxicity cannot be excluded. For the two candidate 
substances in subgroup Ic [FL-no: 13.125 and 13.162] this concern for genotoxicity would preclude 
their evaluation through the Procedure. 
Main group II 
No genotoxicity data were available on any of the 14 sulphur-containing candidate substances in main 
group II, nor on their related supporting substances. As it is anticipated that the predominant metabolic 
attack for these substances will be on the sulphur atom(s), for the candidate substances in main group 
II, ring opening is not considered to be a major metabolic route. The lack of data on the 14 sulphur-
containing candidate substances included in main group II or on related supporting substances does 
not allow to conclude on their potential for genotoxicity. However, this would not preclude the 
evaluation of these 14 candidate substances from subgroup II using the Procedure. 
For a summary of in vitro / in vivo genotoxicity data considered by EFSA, see Table 2.2 and 2.3. 
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3.4. EFSA Considerations 
The Panel considered that the entire group of furans used as chemically defined flavouring substances 
(i.e. all flavouring substances discussed in FGE.13Rev2, FGE.65, FGE.66Rev1 and FGE.67Rev1) is a 
very diverse group. Based on this diversity, the Panel considers it justified to differentiate between the 
various subgroups with respect to the way the substances are metabolised and therefore also with 
respect to their possible genotoxic activity. Information on furan ring oxidation and opening, which 
results in the formation of reactive intermediates, was already considered in FGE.13Rev2. In this FGE, 
for the substances containing oxygenated ring substituents ring-opening was not considered a major 
issue with respect to genotoxicity. This was also supported by the fact that for the supporting 
substance furfural, for which this ring opening also has been reported, data show that furfural is not 
genotoxic in vivo. However for the eight alkyl-substituted furans [FL-no: 13.029, 13.030, 13.059, 
13.069, 13.092, 13.103, 13.106 and 13.148] in this FGE the concern for formation of reactive 
metabolites could not be taken away, because of insufficient data on genotoxicity. It may be 
considered that ring oxidation and opening would be more relevant for these alkyl-substituted furans 
because they lack other simple options for metabolism like hydrolysis and / or immediate conjugation. 
In addition, oxidation of the C1’-carbon of the alkyl substituent results in the formation of a ketone and 
for one such ketone [FL-no: 13.054], data are available to indicate a genotoxic potential (see section 
on genotoxicity on substances in FGE13.Rev2, above and Chapter 4 and Annex III in FGE.13Rev2). 
Therefore, the two candidate alkyl-substituted furans in subgroup Ic of FGE.13Rev2 were not 
evaluated via the Procedure. The same would apply to the eight alkyl-substituted furans in group IV in 
FGE.67Rev1. 
Apart from the alkylfurans, simple hydrolysis / conjugation reactions are also not possible for the 
substances in subgroups V-A and V-C, either. As ethers (group V-A [FL-no: 13.052, 13.061 and 
13.123]) are more resistant to hydrolysis than the corresponding esters, it may be anticipated that these 
ethers can also be more prone to ring oxidations and opening than the substances in subgroup Ia in 
FGE.13Rev2 or group III in FGE.67. The substance in group V-C [FL-no: 13.107] is anticipated to be 
metabolised even more similar to the alkylfurans than the substances in group V-A. Also for  the 
substances in these two groups a concern for genotoxicity cannot be excluded. The concern is not 
identified for the one substance in group V-B, 2,3-dimethylbenzofuran [FL-no: 13.074], because for 
this substance furan ring opening is considered unlikely due to the two methyl substituents at the 
double bond in the furan ring. Another substance in  subgroup V-B [FL-no: 13.031] has been 
considered for genotoxicity in FGE.219, because this substance is an alpha,beta-unsaturated aldehyde. 
Afterwards, the Panel considered that since the double bond in alpha-position to the carbonyl group is 
part of an aromatic system, the reactivity of this double bond is less than in non-aromatic alpha,beta-
unsaturated carbonyls, and for that reason the concern for genotoxicity of this candidate substance 
[FL-no: 13.031] has been waived (EFSA, 2011ac). 
Seven of the nine substances in subgroup VI-B are alpha,beta-unsaturated ketones [FL-no: 13.054, 
13.066, 13.070, 13.083, 13.101, 13.105 and 13.163]. This structural characteristic has been considered 
as an additional reason for concern for genotoxic potential of these substances. However, due to 
structural similarity with acetophenone (i.e. the alpha,beta unsaturated double bond is part of an 
aromatic system and therefore less reactive) the concern for genotoxicity, resulting from the formation 
of such alpha,beta-unsaturated ketones has been lifted (EFSA, 2011ac). Nevertheless, the 
experimentally obtained genotoxicity data indicate that the supporting substance may give rise to 
DNA damage, which may result in chromosomal aberrations rather than gene mutations. The 
formation of DNA-reactive metabolites may be anticipated (EFSA, 2011h). In combination with this, 
the available genotoxicity data are sufficiently strong to raise a concern, which would preclude the 
evaluation of the candidate substance in subgroup VI-B through the Procedure. Based on the concern 
raised by the genotoxicity data on [FL-no: 13.054] and the anticipation that keto-reduction is less 
favourable for biotransformation than e.g. alcohol or aldehyde oxidation and conjugation, the Panel 
considered it necessary to re-evaluate the two remaining alkoyl-substituted furans in subgroup VI-B 
[FL-no: 13.045 and 13.138]. In similarity with the other ketones in this subgroup VI-B in FGE.67Rev1 
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(supported by subgroup Ib in FGE.13Rev2), for these two substances now also a concern for 
genotoxicity is identified. 
No data on genotoxicity are available for the previously evaluated (FGE.13Rev2) furans with sulphur-
containing ring substituents. As it is anticipated that the predominant metabolic attack for these 
substances will be on the sulphur atom(s), for these substances ring opening is also not considered to 
be a major metabolic route. In absence of further data on genotoxicity the Panel decided that these 
substances could be evaluated through the Procedure. In the group of substances evaluated by the 
JECFA (JECFA, 2009a) additional data, both in vitro and in vivo are available on an additional furan 
with a sulphur-containing ring substituent (O-ethyl-S-(2-furylmethyl)thio-carbonate [FL-no: 13.191]). 
This substance is not supporting for the flavouring substances in FGE.13Rev2, FGE.65 and 
FGE.67Rev1. In several good quality in vitro studies (reports also available to EFSA) genotoxicity has 
been observed with this substance, but in a valid micronucleus test in mice in vivo, no genotoxic 
effects were seen. The reports of these studies (Verspeek-Rip, 2000; Verspeek-Rip, 2001); and 
(Meerts, 2000)) were also available to EFSA. In the micronucleus test (Verspeek-Rip, 2001) no 
indications for bone-marrow toxicity were obtained. Although from the clinical signs8 it could be 
anticipated that the substance may have reached the systemic circulation and subsequently the bone-
marrow, given the clearly positive response in vitro, this evidence was considered not strong enough 
and therefore the Panel concluded that this substance should also not be evaluated through the 
Procedure. Thus for one [FL-no: 13.191] of the three flavouring substances in subgroup I [FL-no: 
13.116, 13.190 and 13.191], a concern for genotoxicity was identified, precluding the evaluation of 
this substance through the Procedure. 
Thus, the Panel concluded that 11 of the 33 substances evaluated in this FGE can be evaluated through 
the Procedure [FL-no: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 13.058, 13.074, 
13.116 and 13.190]. For one of the substances in group I [FL-no: 13.191], for all (21) substances in 
groups IV, V-A, V-C and VI-B ([FL-no: 13.029, 13.030, 13.045, 13.052, 13.054, 13.059, 13.061, 
13.066, 13.069, 13.070, 13.083, 13.092, 13.101, 13.103, 13.105, 13.106, 13.107, 13.123, 13.138, 
13.148 and 13.163] a concern for genotoxicity was identified, precluding these substances to be 
evaluated through the Procedure. 
4. Application of the Procedure 
4.1. JECFA Statement on the Application of the Procedure to 40 furan-substituted 
substances evaluated by JECFA9 (JECFA, 2009a) 
As stated above, the main concern with this group arises primarily from the carcinogenicity of furan 
itself, which is believed to involve a reactive genotoxic metabolite formed by epoxidation and opening 
of the furan ring. Furan is not a member of this group of flavouring agents, but all the members of the 
group contain a furan ring with either one or two substituents of varying complexity. In some 
flavouring agents, a substituent is present on one side of the furan ring only, whereas in others, 
substituents are present on both sides. The presence of an extended side-chain attached to the furan 
ring would reduce the potential for epoxidation of the double bond and provide a site for detoxication 
via metabolism and elimination. The flavouring agent that has the simplest structure and would be 
predicted to have the greatest potential for ring oxidation is 2-methylfuran [FL-no: 13.030]; there is 
evidence from studies in vitro and in vivo that this compound undergoes bioactivation to a reactive 
ring-opened metabolite that binds covalently to both protein and DNA. Data are not available on the 
influence of the nature and position of the ring substitution on potential for metabolic activation and 
                                                     
 
8 Clinical signs were: uncoordinated movements, lethargy, rough coat, slow breathing and hunched posture. 
9 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
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adduct formation. After administration of a single dose, 2-methylfuran produced liver toxicity in rats 
from 50 mg/kg bw, but hepatotoxicity has not been reported for other members of this group in more 
extensive studies. 
Testing for genotoxicity has been performed on eight members of this group of flavouring agents. The 
results of the studies of genotoxicity/mutagenicity in vitro that were already available to the 
Committee (the JECFA) at its previous meeting were both positive and negative, with most positive 
results reported for chromosomal aberration. These, however, were less frequent in the presence of 
metabolic activation, indicating possible metabolic detoxication rather than bioactivation. 2-
Methylfuran (FL-no: 13.030), for example, produced chromosomal aberrations in vitro, but the 
clastogenic activity was lower in the presence of a metabolizing system. The limited data available on 
genotoxicity in vivo showed no evidence of chromosomal aberration in mouse bone marrow or 
spermatocytes for 2-methylfuran. 2-Furyl methyl ketone [FL-no: 13.054] also induced no 
chromosomal aberrations in mouse spermatocytes, but a weak, transient increase in chromosomal 
aberrations was observed in mouse bone marrow, associated with mitodepression. O-Ethyl-S-(2- 
furylmethyl)thiocarbonate [FL-no: 13.191] appeared not to induce micronucleus formation in mouse 
bone marrow. 
The new data on 2-furyl methyl ketone [FL-no: 13.054] available to the Committee (the JECFA)  at its 
present meeting were a study on UDS in cultured hepatocytes in vitro, a study on UDS in rat liver in 
vivo/in vitro and a test for SCEs in mouse bone marrow in vivo. 2-Furyl methyl ketone did not induce 
UDS either in vitro or in vivo/in vitro. However, it did induce SCEs, confirming the concern for 
clastogenicity as expressed by the Committee (the JECFA) at its previous meeting. The Committee 
(the JECFA) at its present meeting therefore considered that the new data available did not resolve the 
concerns expressed previously. 
The Committee (the JECFA) concluded that the Procedure for the Safety Evaluation of Flavouring 
Agents could not be applied to this group because of the unresolved toxicological concerns. Studies 
that would assist in the safety evaluation include investigations of the influence of the nature and 
position of ring substitution on metabolism and on covalent binding to macromolecules. Depending on 
the findings, additional studies might include assays related to the mutagenic and carcinogenic 
potential of representative members of this group.” 
4.2. JECFA Statement on the Application of the Procedure to one furfuryl alcohol related 
substance [FL-no: 13.031] evaluated by the JECFA10 (JECFA, 2001b) 
Step 1. 
In applying the Procedure for the Safety Evaluation of Flavouring Agents to the above-mentioned 
substances, the Committee assigned substance 2-benzofurancarboxaldehyde (JECFA No. 751) [FL-no: 
13.031] to structural class III. 
Step 2. 
The JECFA provided no statement on the possible metabolism of substance [FL-no: 13.031]. The 
JECFA concluded that the evaluation of all substances (thus including substance [FL- no: 13.031] in 
this group proceeded via the right-hand (the B-side) side of the scheme (i.e. they cannot be predicted 
to be readily metabolised to innocuous products). 
Step B3. 
                                                     
 
10 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been 
removed. 
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The estimated daily per capita intakes of substance [FL-no: 13.031] is below the threshold of concern 
for its structural class (i.e. 90 µg/day for structural class III). Accordingly, the evaluation of this 
substance proceeded to step B4. 
Step B4. 
For 2-benzofurancarboxaldehyde [FL-no: 13.031], the NOEL of 25 mg/kg bw per day in a 90-day 
feeding study in rats (Posternak et al., 1969) provides an adequate margin of safety (> 1,000,000) in 
relation to the known levels of intake of this substance.  
4.3. Application of the Procedure to 27 Furfuryl and furan derivatives with and without 
additional side-chain substituents and heteroatoms by EFSA11 in FGE.13Rev2 (EFSA, 
2011h) 
In FGE.13Rev2 data have been presented, which indicate that the candidate substance 5-
hydroxymethylfurfuraldehyde (5HMF) [FL-no: 13.139] from subgroup Ia may be metabolised to 5-
[(sulphoxy)methyl]furfural (SMF), which shows genotoxic potential in vitro. Sufficient data have been 
provided to mitigate this concern with respect to genotoxic potential in vivo.  
Based on genotoxicity data for the substance 2-acetylfuran [FL-no: 13.054] supporting to the 
candidate substance in subgroup Ib [FL-no: 13.155], a concern for genotoxicity is raised for candidate 
substance [FL-no: 13.155].  
For the two substances, 2-ethyl-5-methylfuran [FL-no: 13.125] and 2-octylfuran [FL-no: 13.162] from 
subgroup Ic, genotoxicity may be anticipated based on formation of DNA-reactive metabolites and 
based on information available for the candidate substance in subgroup Ib [FL-no: 13.155].  
In absence of sufficient experimental data on genotoxicity on these or structurally related substances, 
the Procedure cannot be applied to the candidate substance in subgroup Ib and the two candidate 
substances in subgroup Ic. A further extensive discussion on the genotoxicity of the candidate 
substances has been presented in Section 8.4 (FGE.13Rev2). 
Thus, the Procedure for the safety evaluation of flavouring substances as outlined in Annex I 
(FGE.13Rev2) has been applied to 24 candidate substances from chemical group 14. The stepwise 
evaluations of the 24 substances are summarised in Table 2a. 
Step 1 
Five [FL-no: 13.122, 13.130, 13.136, 13.139 and 13.145] of the 24 candidate substances evaluated via 
the Procedure are classified into structural class II and 19 [FL-no: 13.011, 13.102, 13.108, 13.113, 
13.114, 13.124, 13.127, 13.129, 13.132, 13.133, 13.135, 13.141, 13.143, 13.144, 13.146, 13.149, 
13.178, 13.185 and 13.199] are classified into structural class III according to the decision tree 
approach by Cramer et al. (Cramer et al., 1978), see Table 2a. 
Step 2 
Taking into account the metabolic pathways described in Section 4 (FGE.13Rev2), none of the 
candidate substances is predicted to be metabolised to innocuous products. Therefore, the evaluation 
of the 24 candidate substances proceeds via the B-side of the evaluation scheme. 
Step B3 
                                                     
 
11 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been 
removed. 
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The five candidate substances, which have been assigned to structural class II, have estimated 
European daily per capita intakes (MSDI) ranging from 0.0024 to 0.39 microgram (Table 3.2). These 
intakes are below the threshold of concern of 540 microgram/person/day for structural class II. The 
estimated daily per capita intakes of the 19 candidate substances assigned to structural class III range 
from 0.0012 to 37 microgram, which are also below the threshold of concern for the structural class of 
90 microgram/person/day. Therefore, the safety evaluation proceeds to step B4 for all 24 candidate 
substances. 
Step B4 
Subgroup Ia structurally related to furfurylalcohol [FL-no: 13.011, 13.102, 13.122, 13.127, 13.129, 
13.130, 13.132, 13.133, 13.136 and 13.139]:  
Considering that the ten candidate substances of subgroup Ia are metabolised to yield furfural and 
furoic acid or furanacrylic acid, the toxicity of the esters of furfuryl alcohol [FL-no: 13.127, 13.129, 
13.130, 13.132 and 13.133], furoic acid [FL-no: 13.102 and 13.122] and furanacrylic acid [FL-no: 
13.011] is expected to be similar to that of the structurally related supporting substance furfural [FL-
no: 13.018] and of the candidate substance 2-furoic acid [FL-no: 13.136], which is the major 
metabolite of furfural. For furfural [FL-no: 13.018] an ADI value of 0.5 mg/kg/d bw has been recently 
established by EFSA (EFSA, 2004c). The estimated daily per capita intakes based on the MSDI 
approach expressed in microgram/kg body weight (bw)/day of candidate substances in subgroup Ia of 
the present FGE.13Rev2 are more than 30.000 fold below the ADI value. 
For 5HMF [FL-no: 13.139] a substantial amount of substance-specific data are available, including 
13-week subchronic studies and chronic studies in B6C3F1 mice and F344/N rats (NTP, 2010c), see 
Section 8.2). The carcinogenicity study in mice demonstrated that 5HMF may induce liver tumours, 
but these are considered irrelevant for humans. In contrast, no carcinogenic responses have been 
reported in the study with rats. The data have shown that the critical effect is cytoplasmic alterations in 
renal proximal tubule epithelium in mice, observed in the 13-weeks study with mice at 188 mg/kg bw 
for 5 days (d)/week (w) and above with an intermittent dose regimen of five days per week. For this 
effects a BMDL of 20.2 bw for 5d/w can be derived, which would be equivalent to 14.4 mg/kg 
bw/day, when corrected for continuous daily administration (see Section 8.2 and Annex V 
(FGE.13Rev2)). When this BMDL of 14.4 mg/kg bw/day derived from the 13-weeks study in mice is 
compared to the MSDI of 0.39 microgram/capita/day for this substance, a margin of safety of 2.2 × 
106 can be calculated. From this it is concluded that 5HMF [FL-no: 13.139] does not raise a safety 
concern as a flavouring substance, at its current level of use in foods. 
Since no toxicity data are available on the sulphur-containing candidate substances in main group II, 
the relevant No Observed Adverse Effect Level (NOAEL) values originate from structurally related 
supporting substances. 
Subgroup IIa sulphides [FL-no: 13.114, 13.124, 13.135, 13.141, 13.143, 13.145 and 13.199]: 
The candidate substances ethyl furfuryl sulfide [FL-no: 13.124], methyl 5-methylfurfuryl sulfide [FL-
no: 13.145] and 2,5-dimethyl-3-(methylthio)furan [FL-no: 13.114] are expected to participate in the 
same metabolic pathways as the supporting substance furfuryl isopropyl sulfide [FL-no: 13.032] and 
therefore to have same toxicological properties. No effects were observed for furfuryl isopropyl 
sulfide in a 90-day dietary study with rats at a single dose level (1.34 mg/kg bw/day) (Posternak et al., 
1969). Comparison of the only level tested with no effect taken as a no observed adverse effect level 
(NOAEL) with the estimated daily per capita intakes based on the MSDI approach and expressed in 
microgram/kg bw/day for ethyl furfuryl sulfide [FL-no: 13.124], methyl 5-methylfurfuryl sulfide [FL-
no: 13.145] and 2,5-dimethyl-3-(methylthio)furan [FL-no: 13.114] provides adequate margins of 
safety > 105. 
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After ester hydrolysis, the candidate substances methyl (2-furfurylthio)acetate and methyl 3-
furfurylthio)propionate [FL-no: 13.141 and 13.143] are anticipated to be metabolised and to have 
toxicological properties similar to the supporting substance ethyl-3-(2-furfurylthio)propionate [FL-no: 
13.093]. For this substance an NOAEL of 5.78 mg/kg bw/day has been identified in a 90-day study 
(Bio-Research Laboratory, 1980). Comparison of this NOAEL with the estimated daily per capita 
intakes based on the MSDI approach and expressed in microgram/kg bw/day of methyl (2-
furfurylthio)acetate and methyl 3-furfurylthio)propionate [FL-no: 13.141 and 13.143] provides an 
adequate margin of safety of 3.2 × 107 for both substances. 
Candidate substances 1-(2-furfurylthio)propanone [FL no: 13.135] and 3-[(2-methyl-3-furyl)thio]-
butanal [FL-no: 13.199] may be evaluated by comparison of their exposure estimates with the NOAEL 
from supporting substance 3-[(2-methyl-3-furyl)thio]-4-heptanone [FL-no: 13.077]. 3-[(2-Methyl-3-
furyl)thio]-4-heptanone was tested in rats at a single dose level of 3.76 mg/kg bw/day in the diet for 90 
days without treatment-related effects (Gallo et al., 1976b). Comparison of the estimated daily per 
capita intake based on the MSDI approach for 3-[(2-methyl-3-furyl)thio]-butanal [FL-no: 13.199] with 
the NOAEL of 3.76 mg/kg bw/day for the supporting substance provided an adequate margin of safety 
of 1.9 × 105. Comparison of the estimated daily per capita intake based on the MSDI approach for 1-
(2-furfurylthio)propanone [FL-no: 13.135] with the NOAEL of 3.76 mg/kg bw/day for the supporting 
substance provides an adequate margin of safety of 2.1 × 107. 
Subgroup IIb thiols [FL-no: 13.108 and 13.149]: 
The candidate substances 5-methyl-2-furanmethanethiol [FL-no: 13.149] is structurally related to the 
supporting substance 2-furanmethanethiol [FL-no: 13.026]. The NOAEL of 2-furanmethanethiol in a 
multiple dose level 91-day oral gavage study with rats was 3 mg/kg bw/day (Phillips et al., 1977). 
Comparison of the NOAEL for 2-furanmethanethiol with the estimated daily per capita intake based 
on the MSDI approach expressed in microgram/kg bw/day of 5-methyl-2-furanmethanethiol [FL-no: 
13.149] provides an adequate margin of safety of 3.7 × 105. 
The candidate substance 4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108] is structurally related 
to the supporting substance 2-methyl-3-thioacetoxy-4,5-dihydrofuran [FL-no: 13.086] from subgroup 
IIe (of FGE13Rev1). Several subchronic studies have been carried out with this supporting substance. 
A NOAEL of 1.4 mg/kg bw/day has been derived in a multiple dose level 13 weeks dietary study with 
rats (Munday and Gellatly, 1973a). Comparison of the NOAEL for 2-methyl-3-thioacetoxy-4,5-
dihydrofuran with the estimated daily per capita intake based on the MSDI approach expressed in 
microgram/kg bw/day of 4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108] provided an 
adequate margin of safety of 2.3 × 103. 
Subgroup IIc disulphides [FL-no: 13.113, 13.144, 13.178 and 13.185]: 
In the previous version of this FGE, the candidate substance 2,5-dimethyl-3-(methyldithio)furan [FL-
no: 13.113] was evaluated against a NOAEL which turned out to belong to a structurally unrelated 
substance. Therefore this evaluation was not valid and thus substance [FL-no: 13.113] had to be 
reconsidered. It may be anticipated that this disulphide will be subject to fission of the disulphide 
bridge. The resulting furan-containing fragment, which is more reactive than the disulphide itself, 
could be evaluated by comparison with the toxicity of 2-methyl-3-furanthiol [FL-no: 13.055] from 
subgroup IIb. The NOAEL of 2-methyl-3-furanthiol in a multiple dose level 90-day oral gavage study 
with rats was 5 mg/kg bw/day (Oser, 1970b). When the NOAEL for 2-methyl-3-furanthiol is 
compared with the estimated daily per capita intake based on the MSDI approach expressed in 
microgram/kg bw/day for 2,5-dimethyl-3-(methyldithio)furan [FL-no: 13.113] an adequate margin of 
safety of 25 × 107 can be calculated. 
For the candidate substances methyl 5-methylfurfuryl disulfide [FL-no: 13.144] and 2-furfuryl 3-oxo-
2-butyl disulphide [FL-no: 13.185] a NOAEL for a comparable substance is not available. However, 
after fission of the disulphide bridge the resulting furan-containing fragment, which is more reactive 
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than the disulphide itself, could be evaluated by comparison with the toxicity of furfuryl mercaptan 
[FL-no: 13.026] from subgroup IIb. The NOAEL of furfuryl mercaptan in a multiple dose level 91-day 
oral gavage study with rats was 3 mg/kg bw/day (Phillips et al., 1977). When the NOAEL for furfuryl 
mercaptan is compared with the estimated daily per capita intakes based on the MSDI approach 
expressed in microgram/kg bw/day for methyl 5-methylfurfuryl disulfide [FL-no: 13.144] and 2-
furfuryl 3-oxo-2-butyl disulphide [FL-no: 13.185], adequate margins of safety of 75 × 106 and 16 × 
106, respectively, can be calculated. 
The Panel noted that the candidate substance 3-(furfuryldithio)-2-methylfuran [FL-no: 13.178] is 
identical to [FL-no: 13.192]. The latter substance has been assigned the JECFA number 1524 in the 
report of the 69th meeting (JECFA, 2009a). For this substance, in the JECFA evaluation, an MSDI for 
Europe of 0.24 microgram per capita per day was given. This figure, which is higher and more recent 
than the exposure estimate in the previous version of this FGE (0.0012 microgram per capita per day), 
will be used in the current revision of this FGE. The candidate substance 3-(furfuryldithio)-2-
methylfuran [FL-no: 13.178] is structurally related to the supporting substance bis(2-methyl-3-furyl) 
disulfide [FL-no: 13.016] which has been tested in two single-dose-level 90-day dietary studies with 
rats at 5 mg/kg bw/day and 0.45 mg/kg bw/day, respectively (Oser, 1970a; Morgareidge and Oser, 
1970e). Treatment-related effects were seen at the intake level of 5.0 mg/kg bw/day, but the intake 
level of 0.45 mg/kg bw/day was determined to be a NOAEL. The disulphide bridge fission products 
are related to [FL-no: 13.026] (of subgroup IIb), for which a NOAEL of 3 mg/kg bw/day has been 
derived. When the estimated daily per capita intake based on the MSDI approach expressed in 
microgram/kg bw/day of 3-(furfuryldithio)-2-methylfuran [FL-no: 13.178] is compared to this 
NOAEL an adequate margins of safety of 7.5 × 105 can be calculated for [FL-no: 13.178].  
Alternatively, the two fission products may be considered separately. These fission products are [FL 
no: 13.055] and [FL-no: 13.026], for which NOAELs of 5 mg/kg bw/day and 3 mg/kg bw/day, 
respectively, have been derived (Oser, 1970b; Phillips et al., 1977). Exposure to [FL-no: 13.178] at the 
level of its MSDI would correspond to exposures to [FL-no: 13.026] and [FL-no: 13.055] of 0.12 
microgram per person per day for both fragments. Comparison of these exposure estimates to the 
NOAELs for these two fragments provides adequate margins of safety of 1.5 × 106 and 2.5 × 106 for 
[FL-no: 13.026] and [FL-no: 13.055], respectively. 
Subgroup IId polysulphide [FL-no: 13.146]: 
The one candidate flavouring substance in this subgroup methyl furfuryl trisulphide [FL-no: 13.146] is 
a trisulphide which may be anticipated to release perthiols upon metabolism. Similar reactive products 
may be anticipated for bis-(2-methyl-3-furyl)tetrasulphide [FL-no: 13.017] for which a NOAEL of 
0.56 mg/kg bw/day in a 90-day study has been derived (Morgareidge and Oser, 1970f). Comparison of 
this NOAEL with the estimated daily per capita intake of methyl furfuryl trisulphide [FL-no: 13.146] 
based on the MSDI approach expressed in microgram/kg bw/day of 0.0024 microgram provides an 
adequate margin of safety of 14 × 106. 
Summary: 
For the ten, seven, two, four and one substances in subgroups Ia [FL-no: 13.011, 13.102, 13.122, 
13.127, 13.129, 13.130, 13.132, 13.133, 13.136 and 13.139], IIa [FL-no: 13.114, 13.124, 13.135, 
13.141, 13.143, 13.145 and 13.199], IIb [FL-no: 13.108 and 13.149], IIc [FL-no: 13.113, 13.144, 
13.178 and 13.185] and IId [FL-no: 13.146], respectively, which have been evaluated through the 
Procedure, it can be concluded at step B4 of the Procedure that these 24 candidate substances do not 
pose a safety concern when used as flavouring substances at the estimated levels of intake based on 
the MSDI approach. 
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4.4. EFSA Considerations 
For eight of the 33 flavouring substances [FL-no: 13.006, 13.021, 13.022, 13.023, 13.024, 13.116, 
13.190 and 13.191], the classification according to Cramer et al., 1977 was revised from structural 
class II to III. These revisions are due to the question of natural occurrence for the substances involved 
and were consistent with FGE.13Rev2 and FGE.65. The Panel notes that for the substances involved, 
this will not affect the final conclusions. 
The Panel agrees with the JECFA (JECFA, 2009a) for 22 of the 33 substances [FL-no: 13.029, 13.030, 
13.045, 13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.092, 13.101, 13.103, 
13.105, 13.106, 13.107, 13.123, 13.138, 13.148, 13.163 and 13.191] in the group of furan-substituted 
aliphatic hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids and related esters, sulfides, 
disulfides and ethers that these substances cannot be evaluated through the Procedure, based on 
concerns with respect to genotoxicity and carcinogenicity. 
The Panel also agrees with the conclusion reached by the JECFA at its 55th meeting (JECFA, 2001b) 
that substance [FL-no: 13.031] can be evaluated using the Procedure, and that this substances poses no 
safety concern when used as a flavouring substance. 
Contrary to the JECFA and in line with the decisions taken in previous FGEs (FGE.13.Rev2, 
FGE.66Rev1, FGE.67 (EFSA, 2011h; EFSA, 2011ad; EFSA, 2009ao)), the Panel considers that the 
remaining 10 substances [FL-no: 13.006, 13.021, 13.022, 13.023, 13.024, 13.047, 13.058, 13.074, 
13.116 and 13.190] can also be evaluated using the Procedure. 
Step 1 
These 10 substances which can be evaluated through the Procedure [FL-no: 13.006, 13.021, 13.022, 
13.023, 13.024, 13.047, 13.058, 13.074, 13.116, and 13.190] have been allocated to structural class III 
according to the Cramer et al. decision tree.  
Step 2 
In line with the previous evaluations (FGE.13.Rev2, FGE.66Rev1 and FGE.65 (EFSA, 2011h; EFSA, 
2011ad; EFSA, 2009ao)), none of the 10 substances can be anticipated to be metabolised to innocuous 
products. Therefore all 10 substances should be evaluated through the B-side of the Procedure. 
Step B3 
At step B3 of the Procedure, all 10 substances have exposure estimates less than the thresholds for 
their respective classes, and therefore these substances should proceed to step B4 of the Procedure. 
Step B4 
Phenethyl 2-furoate [FL-no: 13.006] 
After hydrolysis this substance will yield 2-furoic acid [FL no: 13.019] and phenethyl alcohol [FL no: 
02.019]. At an exposure at the level of the MSDI (0.012 μg per capita per day), the respective 
amounts of 2-furoic acid and phenethyl alcohol would amount to 0.006 μg per person per day and 
0.007 μg per person per day, respectively. In FGE.13Rev1 2-furoic acid has been evaluated by 
comparison with the ADI of 0.5 mg/kg bw for the related substance 2-furfural (EFSA, 2004c). 
Phenethyl alcohol was considered of no safety concern at step A3 of the Procedure by the Panel in 
FGE.53. Based on these considerations, it is concluded that at the estimated level of exposure, based 
on the MSDI approach, phenethyl 2-furoate [FL-no: 13.006] is of no safety concern. 
2,5-Dimethyl-3-thioacetoxyfuran [FL-no: 13.116] 
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At step B4 of the Procedure the exposure estimate of 3 microgram per capita per day for [FL-no: 
13.116] can be compared to the NOAEL of 0.73 mg/kg bw/day for the supporting substance 2,5-
dimethyl-3-(isopentylthio)furan [FL-no: 13.041] (FGE.65 (EFSA, 2009an)), as determined in a 90-day 
study reported by Morgareidge et al. (Morgareidge et al., 1974a) and Cox et al., (Cox et al., 1974a). 
An adequate margin of safety of 14.6 ×103 can be calculated. 
3-((2-Methyl-3-furyl)thio)-2-butanone [FL-no: 13.190] 
At step B4 of the Procedure the exposure estimate of 0.012 microgram per capita per day for [FL-no: 
13.190] can be compared to the NOAEL of 3.76 mg/kg bw/day for the supporting substance 3-((2-
methyl-3-furyl)thio)heptan-4-one [FL-no: 13.077] (FGE.65 (EFSA, 2009an)), as determined in a 90-
day study reported by Gallo et al. (Gallo et al., 1976b). An adequate margin of safety of 1.9 ×107 can 
be calculated. 
Isopentyl 4-(2-furan)butyrate [FL-no: 13.021], Ethyl 3(2-furyl)propionate [FL-no: 13.022], Isopentyl 
3-(2-furan)propionate [FL-no: 13.023] and Isobutyl 3-(2-furyl)propionate [FL-no: 13.024] 
At step B4 of the Procedure for substance [FL-no: 13.024] a NOAEL of 35 mg/kg bw/day, determined 
in a 90-day study, has been reported (Lough et al., 1985). When at step B4 the NOAEL for this 
substance is compared to its exposure estimate of 0.12 microgram per capita per day based on the 
MSDI approach, an adequate margin of safety of 18 × 106 can be calculated. The same NOAEL can 
also be used to evaluate [FL-no: 13.021, 13.022 and 13.023], for which exposure estimates of 0.24, 
0.012 and 0.24 microgram per capita per day were calculated. Comparison of these MSDI exposure 
estimates with the NOAEL for [FL-no: 13.024] provides adequate margins of safety of 8.9 ×106, 1.8 
×108 and 8.9 × 106 for [FL-no: 13.021, 13.022 and 13.023], respectively. 
2,3-Dimethylbenzofuran [FL-no: 13.074] 
At step B4 of the Procedure for substance [FL-no: 13.074] a NOAEL of 0.6 mg/kg bw/day, 
determined in a 90-day study has been reported (Long et al. (Long, 1977a). When at step B4 the 
NOAEL for this substance is compared to its exposure estimate of 0.52 microgram per capita per day 
based on the MSDI approach, an adequate margin of safety of 69 × 103 can be calculated. 
Propyl 3-(2-furyl)acrylate [FL-no: 13.047] 
This substance can be anticipated to be hydrolysed into propanol and 2-furanacrylic acid. The latter 
fragment should be further considered. At an exposure at the level of the MSDI (2.2 μg per capita per 
day) for [FL no: 13.047], the amount of 2-furanacrylic acid released would amount to 1.7 μg per 
person per day. In FGE.13Rev1 2-furanacrylic acid has been evaluated by comparison with the ADI of 
0.5 mg/kg bw for the related substance 2-furfural (EFSA, 2004c). It may be concluded that at the 
estimated level of exposure, based on the MSDI approach, propyl 3-(2-furyl)acrylate [FL-no: 13.047] 
is of no safety concern. 
3-(5-Methyl-2-furyl) butanal [FL-no: 13.058] 
No NOAEL could be identified to support the evaluation of substance [FL-no: 13.058] at step B4. 
Therefore for this substance no conclusion as to its safety when used as a chemically defined 
flavouring substance can be reached.  
5. Conclusion 
The present Flavouring Group Evaluation deals with 39 substances, 38 substances of which were 
previously considered by the JECFA in a group of 40 furan-substituted aliphatic hydrocarbons, 
alcohols, aldehydes, ketones, carboxylic acids and related esters, sulfides, disulfides and ethers 
(JECFA, 2009a). One of these 40 substances [FL-no: 13.192] appeared to be a synonym of substance 
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[FL-no: 13.178] which has already been evaluated in FGE.13Rev2. Therefore this substance [FL-no: 
13.192] will not be further considered in this FGE and should be removed from the Register. Another 
substance [FL-no: 13.176] will be evaluated in FGE.75 rather than FGE.67, because of better 
structural similarity with candidate substances in FGE.75. Furthermore, one candidate substance [FL-
no: 13.031] from FGE.66Rev1 has been included in this revision of FGE.67, because this substance 
has better structural similarity to a candidate flavouring substance [FL-no: 13.074] in FGE.67 than to 
the other candidate flavouring substances in FGE.66Rev1. The flavouring substances considered in 
this FGE have been allocated to various subgroups, based on their chemical structures. 
Thirteen of the 15 substances in subgroups VI-A and VI-B are alpha,beta-unsaturated carbonyls, 
which have been evaluated by EFSA in FGE.19 context with respect to a concern for a possible 
genotoxic potential. This concern for genotoxicity could not be alleviated for the six substances in 
subgroup VI-A [FL-no: 13.034, 13.043, 13.044, 13.046, 13.137 and 13.150], corresponding to FGE.19 
subgroup 4.6 (EFSA, 2008b). These six substances were therefore not further considered in this FGE. 
The thirty-three candidate substances considered in this FGE [FL-no: 13.006, 13.021, 13.022, 13.023, 
13.024, 13.029, 13.030, 13.031, 13.045, 13.047, 13.052, 13.054, 13.058, 13.059, 13.061, 13.066, 
13.069, 13.070, 13.074, 13.083, 13.092, 13.101, 13.103, 13.105, 13.106, 13.107, 13.116, 13.123, 
13.138, 13.148, 13.163, 13.190 and 13.191] are structurally related to the group of 27 furfuryl and 
furan derivatives evaluated by EFSA in FGE.13Rev2. Part of the substances is also structurally related 
to a group of 33 sulphur-substituted furan derivatives used as flavouring agents, evaluated by EFSA in 
FGE.65 and another part is structurally related to 14 furfuryl derivatives evaluated in FGE.66Rev1 
(EFSA, 2009an; EFSA, 2011ad). 
For eight alkyl-substituted furans in group IV [FL-no: 13.029, 13.030, 13.059, 13.069, 13.092, 13.103, 
13.106 and 13.148]  for three furfuryl ethers in subgroup V-A [FL-no: 13.052, 13.061 and 13.123] and 
a difurfuryl furan [FL-no: 13.107] in subgroup V-C and a sulphur-substituted furan from group I [Fl 
no: FL-no: 13.191] a concern for genotoxicity was identified. 
For the seven alpha,beta-unsaturated substances in subgroup VI-B [FL-no: 13.054, 13.066, 13.070, 
13.083, 13.101, 13.105 and 13.163], corresponding to FGE.19 subgroup 4.5 (EFSA, 2008b) no 
concern for genotoxicity with respect to this alpha,beta-unsaturation was identified afterwards, based 
on additional evaluation of their chemical structures. However, based on available genotoxicity data, a 
concern for genotoxicity was still identified, which was also relevant for the two remaining substances 
[FL-no: 13.045 and 13.138] in this subgroup. 
Thus, the Panel agrees with JECFA for 22 of the 33 substances [FL-no: 13.029, 13.030, 13.045, 
13.052, 13.054, 13.059, 13.061, 13.066, 13.069, 13.070, 13.083, 13.092, 13.101, 13.103, 13.105, 
13.106, 13.107, 13.123, 13.138, 13.148, 13.163 and 13.191] that these substances cannot be evaluated 
through the procedure, based on concerns with respect to genotoxicity. 
In line with the decisions taken in previous FGEs (FGE.13Rev2, FGE.65 and FGE.66Rev1), the Panel 
considers that 11 substances [FL-no: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 13.058, 
13.074, 13.116 and 13.190] can be evaluated using the Procedure. 
It was concluded for ten substances [FL-no: 13.006, 13.021, 13.022, 13.023, 13.024, 13.031, 13.047, 
13.074, 13.116 and 13.190], that they would be of no safety concern at their estimated intake levels 
based on the MSDI approach. For the remaining substance [FL-no: 13.058] this conclusion could not 
be drawn due to lack of an adequate NOAEL. 
For all 33 substances use levels are needed to calculate the mTAMDIs in order to identify those 
flavouring substances that need more refined exposure assessment and to finalise the evaluation. 
In order to determine whether the conclusion for the evaluated substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
including complete purity criteria and identity are available for 30 of the 33 substances. Information 
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on stereoisomeric composition has not been submitted for [FL-no: 13.047]. Information on solubility 
in water is missing for [FL-no: 13.045] and information on melting point is missing for [FL-no: 
13.031]. 
Thus, for 25 of the 33 substances considered in this FGE the Panel has reservations. For three 
substances [FL-no: 13.031, 13.045 and 13.047] data on specifications / stereoisomerism are missing. 
For 23 substances [FL-no: 13.029, 13.030, 13.045, 13.052, 13.054, 13.058, 13.059, 13.061, 13.066, 
13.069, 13.070, 13.083, 13.092, 13.101, 13.103, 13.105, 13.106, 13.107, 13.123, 13.138, 13.148, 
13.163 and 13.191] the Panel concluded that additional toxicity / genotoxicity data are required.  
For the remaining eight of these 33 furan derivatives [FL-no: 13.006, 13.021, 13.022, 13.023, 13.024, 
13.074, 13.116 and 13.190] the Panel concluded that they would be of “no safety concern at estimated 
levels of intake as flavouring substances” based on the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY  
 
Table 1: Specification Summary for 33 furan derivatives evaluated by JECFA (JECFA, 2005d) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
13.006 
1517 
Phenethyl 2-furoate 
O
O
O 2865 
362 
7149-32-8 
Liquid 
C13H12O3 
216.24 
Insoluble 
Soluble 
275 
 
NMR 
96 % 
1.585-1.593 
1.136-1.142 
 
 
13.021 
1516 
Isopentyl 4-(2-furan)butyrate O O
O  
2070 
2080 
7779-66-0 
Liquid 
C13H20O3 
224.30 
Insoluble 
Insoluble 
263-265 
 
NMR 
95 % 
1.551-1.555 
0.975-0.981 
 
 
13.022 
1513 
Ethyl 3(2-furyl)propionate 
O
O
O 2435 
2091 
10031-90-0 
Solid 
C9H12O3 
168.19 
Very slightly soluble 
Soluble 
n.a. 
24-25 
NMR 
95 % 
n.a. 
n.a. 
Register name to be 
changed to: Ethyl 3-(2-
furyl)propionate. 
 
13.023 
1515 
Isopentyl 3-(2-furan)propionate 
O
O
O 2071 
2092 
7779-67-1 
Liquid 
C12H18O3 
210.27 
Insoluble 
Soluble 
258 
 
NMR 
96 % 
1.549-1.557 
0.987-0.993 
 
 
13.024 
1514 
Isobutyl 3-(2-furyl)propionate 
O
O
O 2198 
2093 
105-01-1 
Liquid 
C11H16O3 
196.25 
Very slightly soluble 
Soluble 
105 (4 hPa) 
 
NMR 
96 % 
1.531-1.537 
1.007-1.013 
 
 
13.029 
1488 
2,5-Dimethylfuran O
 
 
2208 
625-86-5 
Liquid 
C6H8O 
96.13 
Slightly soluble 
Soluble 
93 
 
IR NMR MS 
95 % 
1.437-1.443 
0.892-0.898 
 
 
13.030 
1487 
2-Methylfuran O
 
4179 
2209 
534-22-5 
Liquid 
C5H6O 
82.10 
Slightly soluble 
Soluble 
64 
 
IR NMR MS 
97 % 
1.431-1.437 
0.908-0.917 
 
 
13.031 
751 
2-Benzofurancarboxaldehyde OO
 
3128 
2247 
4265-16-1 
Solid 
C9H6O2 
146.15 
Insoluble 
Slightly soluble 
130-131 (17hPa) 
 
MS 
96 % 
n.a. 
n.a. 
MP 7). 
 
13.045 
1508 
1-(2-Furyl)-propan-2-one O
O  
2496 
11837 
6975-60-6 
Liquid 
C7H8O2 
124.14 
 
Soluble 
179-180 
 
NMR 
97 % 
1.499-1.505 
1.074-1.080 
Missing data on 
solubility in water. 
13.047 
1518 
Propyl 3-(2-furyl)acrylate   6) 
O
O
O 2945 
11842 
623-22-3 
Liquid 
C10H12O3 
180.20 
Insoluble 
Soluble 
119 (9 hPa) 
 
NMR 
97 % 
1.520-1.526 
1.071-1.077 (20°) 
Stereoisomeric 
composition to be 
specified. 
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Table 1: Specification Summary for 33 furan derivatives evaluated by JECFA (JECFA, 2005d) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
13.052 
1520 
Furfuryl methyl ether O
O
 
3159 
10944 
13679-46-4 
Liquid 
C6H8O2 
112.13 
Insoluble 
Soluble 
134-135 
 
NMR 
99 % 
1.454-1.460 
1.013-1.019 
 
 
13.054 
1503 
2-Acetylfuran 
O
O 3163 
11653 
1192-62-7 
Liquid 
C6H6O2 
110.11 
Very slightly soluble 
Soluble 
67 (13 hPa) 
 
IR 
97 % 
1.505-1.510 
1.102-1.107 
 
 
13.058 
1500 
3-(5-Methyl-2-furyl) butanal 
O
O
3307 
10355 
31704-80-0 
Liquid 
C9H12O2 
152.19 
Insoluble 
Soluble 
88-91 (16 hPa) 
 
NMR 
98 % 
1.575-1.581 
1.006-1.012 
Racemate. 
13.059 
1491 
2-Pentylfuran O
 
3317 
10966 
3777-69-3 
Liquid 
C9H14O 
138.21 
Slightly soluble 
Soluble 
58-60 (13 hPa) 
 
NMR 
99 % 
1.443-1.449 
0.886-0.893 
 
 
13.061 
1522 
Difurfuryl ether 
O
O
O
 
3337 
10930 
4437-22-3 
Liquid 
C10H10O3 
178.19 
Insoluble 
Soluble 
88-89 (1 hPa) 
 
NMR 
97 % 
1.138-1.144 
1.506-1.512 
 
 
13.066 
1506 
3-Acetyl-2,5-dimethylfuran O
O
3391 
10921 
10599-70-9 
Liquid 
C8H10O2 
138.17 
Slightly soluble 
Soluble 
83 (14 hPa) 
 
NMR 
99 % 
1.484-1.492 
1.027-1.048 
 
 
13.069 
1492 
2-Heptylfuran O
 
3401 
10952 
3777-71-7 
Liquid 
C11H18O 
166.26 
Insoluble 
Soluble 
209-210 
 
NMR 
99 % 
1.446-1.452 
0.860-0.866 
 
 
13.070 
1512 
2-Hexanoylfuran 
O
O 3418 
11180 
14360-50-0 
Liquid 
C10H14O2 
166.22 
Slightly soluble 
Soluble 
65-67 (0.7 hPa) 
 
NMR 
99 % 
1.490-1.496 
0.992-0.998 
 
 
13.074 
1495 
2,3-Dimethylbenzofuran 
O
3535 
11913 
3782-00-1 
Liquid 
C10H10O 
146.19 
Insoluble 
Soluble 
96-98 (20 hPa) 
 
NMR 
97 % 
1.554-1.563 
1.031-1.037 
 
 
13.083 
1504 
2-Acetyl-5-methylfuran 
O
O 3609 
11038 
1193-79-9 
Liquid 
C7H8O2 
124.14 
Slightly soluble 
Soluble 
71-72 (10 hPa) 
 
IR NMR 
99 % 
1.511-1.517 
1.066-1.072 (20°) 
 
 
13.092 
1489 
2-Ethylfuran O
 
3673 
11706 
3208-16-0 
Liquid 
C6H8O 
96.13 
Insoluble 
Soluble 
92-93 
 
NMR 
95 % 
1.444-1.450 
0.909-0.915 
 
 
Flavouring Group Evaluation 67, Revision 1
 
 
38 EFSA Journal 2011; 9(10):2315 
Table 1: Specification Summary for 33 furan derivatives evaluated by JECFA (JECFA, 2005d) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
13.101 
1505 
2-Acetyl-3,5-dimethylfuran 
O
O 4071 
 
22940-86-9 
Liquid 
C8H10O2 
138.17 
Insoluble 
Soluble 
195 
18 
MS 
95 % 
1.494-1.500 
1.041-1.047 
 
 
13.103 
1490 
2-Butylfuran O
 
4081 
10927 
4466-24-4 
Liquid 
C8H12O 
124.18 
Insoluble 
Soluble 
139 
 
MS 
95 % 
1.444-1.450 
0.884-0.890 
 
 
13.105 
1507 
2-Butyrylfuran 
O
O 4083 
11045 
4208-57-5 
Liquid 
C8H10O2 
138.17 
Insoluble 
Soluble 
195 
 
NMR MS 
95 % 
1.489-1.495 
1.050-1.056 
 
 
13.106 
1493 
2-Decylfuran O
 
4090 
 
83469-85-6 
Solid 
C14H24O 
208.34 
Insoluble 
Soluble 
 
30 
NMR 
95 % 
n.a. 
n.a. 
 
 
13.107 
1496 
2,4-Difurfurylfuran OO
O  
4095 
 
64280-32-6 
Solid 
C14H12O3 
228.24 
Insoluble 
Soluble 
 
153 
NMR 
95 % 
n.a. 
n.a. 
 
 
13.116 
1523 
2,5-Dimethyl-3-thioacetoxyfuran O
S
O
 
4034 
 
55764-22-2 
Liquid 
C8H10O2S 
170.23 
Practically insoluble 
Soluble 
230 
 
IR NMR MS 
98 % 
1.527-1.533 
1.137-1.143 
 
 
13.123 
1521 
Ethyl furfuryl ether O
O
 
4114 
10940 
6270-56-0 
Liquid 
C7H10O2 
126.15 
Slightly soluble 
Soluble 
150 
 
MS 
95 % 
1.449-1.455 
0.982-0.988 
 
 
13.138 
1510 
1-(2-Furyl)butan-3-one 
O
O 4120 
11084 
699-17-2 
Solid 
C8H10O2 
138.17 
Slightly soluble 
Soluble 
n.a. 
37 
MS 
95 % 
n.a. 
n.a. 
 
 
13.148 
1494 
3-Methyl-2(3-methylbut-2-enyl)furan 
O
4174 
 
15186-51-3 
Liquid 
C10H14O 
150.22 
Slightly soluble 
Soluble 
70 (15 hPa) 
 
MS 
98 % 
1.473-1.479 
0.998-1.004 
Register name to be 
changed to: 3-Methyl-
2/(3-methylbut-2-
enyl)furan. 
 
13.163 
1509 
2-Pentanoylfuran 
O
O 4192 
 
3194-17-0 
Liquid 
C9H12O2 
152.19 
Slightly soluble 
Soluble 
101 (13 hPa) 
 
MS 
95 % 
1.486-1.492 
1.009-1.015 
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Table 1: Specification Summary for 33 furan derivatives evaluated by JECFA (JECFA, 2005d) 
FL-no 
JECFA-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
EFSA comments 
13.190 
1525 
3-((2-Methyl3-furyl)thio)-2-butanone O
S
O  
4056 
 
61296-44-1 
Liquid 
C9H12O2S 
184.25 
Practically insoluble 
Soluble 
70 (1 hPa) 
 
IR NMR MS 
99 % 
1.510-1.516 
1.104-1.110 
CASrn in Register is 
not valid; CASrn to be 
changed to: 61295-44-
1 (The Good Scents 
Company, 2011). 
Reister name to be 
changed to 3-((2-
Methyl-3-furyl)thio)-2-
butanone. 
Racemate. 
13.191 
1526 
o-Ethyl S-(2-
furylmethyl)thiocarbonate O
S O
O 4043 
 
376595-42-5 
Liquid 
C8H10O3S 
186.23 
Practically insoluble 
Soluble 
130-135 
 
IR NMR MS 
99 % 
1.504-1.510 
1.167-1.173 
 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
6) Stereoisomeric composition not specified. 
7) MP: Missing melting point. 
 
Flavouring Group Evaluation 67, Revision 1
 
 
40 EFSA Journal 2011; 9(10):2315 
TABLE 2: GENOTOXICITY DATA  
TABLE 2.1: GENOTOXICITY DATA FOR 40 FURAN-SUBSTITUTED SUBSTANCES EVALUTED BY JECFA (JECFA, 2009A) 
FL-no: 
JECFA-no: 
Flavouring agent End-point Test system Concentration/ dose Results References 
In vitro 
13.030 
1487 
 
2-Methylfuran   
  
Reverse mutation   Salmonella typhimurium  TA98 and 
TA100  
0.165, 0.330, 0.495 or 0.660 µmol/plate 
(13.5, 27.1, 40.6 or 54.2 µg/plate)a  
Negativeb   (Shinohara et al., 1986)  
Reverse mutation   S. typhimurium TA98,  TA100, TA102 
and TA1535  
Up to 10 000 µg/plate   Negativeb,c,d  (Zeiger et al., 1992)  
Reverse mutation   S. typhimurium TA97 and  TA104  Up to 10 000 µg/plate   Equivocalb,c,d  (Zeiger et al., 1992)  
Reverse mutation   S. typhimurium TA98,  TA100 and 
TA102 
11 nmol/plate to 1,1 mmol/ plate (0,9-90 
310 µg/plate)a   
Negativeb   (Aeschbacher et al., 1989)  
DNA damage   Bacillus subtilis H17 (rec+)  and M45 
(rec˜)   
0.16, 16 or 1600 µg/disc   Negative 
Positiveb,e 
(Shinohara et al., 1986)  
Chromosomal aberration  CHO cells   0-150 mmol/l   
(0-12315 µg/ml)a  
Positiveb,f   (Stich et al., 1981b) 
13.029 
1488 
 
2,5-Dimethylfuran   
  
Reverse mutation  S. typhimurium TA98 and  TA100   0.165, 0.330, 0.495 or 0.660 µmol/plate 
(13.5, 27.1, 40.6 or 54.2 µg/plate)g  
Negativeb   (Shinohara et al., 1986) 
Reverse mutation   S. typhimurium TA98  and TA100  Not specified   Negativeb   (Lee et al., 1994a) 
Reverse mutation   S. typhimurium TA97,  TA98, TA100 
and TA1535   
Up to 3333 µg/plate   Negativeb,c,d   (Zeiger et al., 1992) 
DNA damage   B. subtilis H17 (rec+)  and M45 (rec-)  190, 1900 or 9500 µg/disc   Negative 
Positiveb,h   
(Shinohara et al., 1986) 
Chromosomal aberration Chinese hamster V79  cells 1 mmol/l (96.13 µg/ml)g   Negative   (Ochi and Ohsawa, 1985) 
Chromosomal aberration CHO cells   0-20 mmol/l  (0-1923 µg/ml)g   Positiveb,f   (Stich et al., 1981b) 
13.148 
1494 
3 -Methyl-2-(3-methylbut-2-enyl)-
furan  
Reverse mutation   S. typhimurium TA98, TA100, TA1535 
and TA1537 
3.2, 16, 80, 400 or 2000 µg/plate   Negativeb   (Asquith, 1989a) 
13.034 
 
3-(2-Furyl)acrolein   
  
Reverse mutation   S. typhimurium TA100  Not specified   Negativeb,c   (Eder et al., 1991b) 
DNA damage (SOS 
chromotest)   
E. coli PQ37  Not specified   Negativei   (Eder et al., 1991b) 
DNA damage (SOS 
chromotest)   
E. coli PQ37  Not specified   Weakly positivej   (Eder et al., 1993) 
13.054 
1503 
 
2-Furyl methyl ketone   
  
Reverse mutation   S. typhimurium TA98  and TA100   0.165, 0.330, 0.495 or 0.660 µmol/plate 
(13.5, 27.1, 40.6 or 54.2 µg/plate)j  
Negative 
Positiveb,k   
(Shinohara et al., 1986) 
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TABLE 2.1: GENOTOXICITY DATA FOR 40 FURAN-SUBSTITUTED SUBSTANCES EVALUTED BY JECFA (JECFA, 2009A) 
FL-no: 
JECFA-no: 
Flavouring agent End-point Test system Concentration/ dose Results References 
 2-Furyl methyl ketone  (cont.) 
  
DNA damage   E. coli PQ37 (SOS   chromotest)  Not specified   Slightly positivej   (Eder et al., 1993) 
DNA damage   B. subtilis H17 (rec+)  and M45 (rec-)   550, 5500 or  55000 µg/disc   Negative 
Positiveb,l   
(Shinohara et al., 1986) 
Chromosomal aberration CHO cells 0-112.6 mmol/l  
(0-13220 µg/ml)j   
Positiveb,m,n (Stich et al., 1981b) 
UDS Human hepatocytes 2.19, 4.38, 8.75, 17.5, 35, 70, 140 or 280 
µg/ml   
Negative (Durward, 2007a) 
13.044 
1511 
4-(2-Furyl)-3-buten-2-one   Reverse mutation S. typhimurium TA98, TA100, TA1535 
and TA1537  
33, 100, 333, 1000, 2166 or 3333 µg/ plate   Negativeb,c,o (Mortelmans et al., 1986) 
13.022 
1513 
Ethyl 3-(2-furyl)propanoate   Reverse mutation S. typhimurium TA98, TA100, TA1535, 
TA1537 and TA1538 
Up to 3600 µg/plate   Negativeb (Wild et al., 1983) 
13.191 
1526 
 
O-Ethyl-S-(2-furylmethyl)thio- 
carbonate 
  
Reverse mutation S. typhimurium TA98, TA100, TA1535 
and TA1537 
33, 100, 333, 1000 or 3330 µg/plate   Negativeb,p (Verspeek-Rip, 2000) 
Reverse mutation E. coli WP2uvrA 33, 100, 333, 1000 or   3330 µg/plate   Negativeb,q (Verspeek-Rip, 2000) 
Chromosomal aberration Human peripheral lymphocytes 150, 300 or  350 µg/ml Negativeb,r (Meerts, 2000) 
Chromosomal aberration Human peripheral lymphocytes 130, 240 or 280 µg/ml   Positivei,s (Meerts, 2000) 
Chromosomal aberration Human peripheral lymphocytes 100, 130 or 240 µg/ml   Positivei,t (Meerts, 2000) 
Chromosomal aberration Human peripheral  lymphocytes 150, 325 or 375 µg/ml   Negative 
Positiver,u,v 
(Meerts, 2000) 
 In vivo 
13.030 
1487 
2-Methylfuran   Chromosomal aberration Mouse bone marrow  cells and 
spermatocytes 
1000, 2000 or 4000 mg/kg (100, 200 or 400 
mg/kg bw per day)w   
Negative (Subramanyam et al., 1989) 
13.054 
1503 
 
2-Furyl methyl ketone   
  
Chromosomal aberration Mouse bone marrow 1000, 2000 or 3000  mg/l (20, 40 or 60 mg/  
kg bw)x   
Positivey,z (Sujatha et al., 1993) 
Chromosomal aberration Mouse spermatocytes  1000, 2000 or 3000  mg/l (20, 40 or 60 mg/ 
kg bw)x   
Negativeaa (Sujatha et al., 1993) 
SCE Mouse bone marrow 1000, 2000 or 3000  mg/l (20, 40 or 60 mg/   
kg bw)x   
Positive (Sujatha, 2007) 
UDS Rat liver 7 or 21 mg/kg bw   Negative (Durward, 2007b) 
13.191 
1526 
O-Ethyl-S-(2-furylmethyl)thio-
carbonate 
Micronucleus induction Mouse bone marrow 100, 250 or 500 mg/kg bwbb   Negative (Verspeek-Rip, 2001) 
CHO, Chinese hamster ovary; SCE, sister chromatid exchange; UDS, unscheduled DNA synthesis. 
a Calculated using relative molecular mass of 2-methylfuran = 82.1. 
b With and without metabolic activation. 
c Preincubation method. 
d Occasional incidences of slight to complete clearing of the background lawn at the higher concentrations. 
e Negative at all concentrations with metabolic activation; positive without metabolic activation. 
f Clastogenic activity decreased with metabolic activation (statistical significance of results was not specified). 
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g Calculated using relative molecular mass of 2,5-dimethylfuran = 96.13. 
h Positive at every concentration without metabolic activation; with metabolic activation, negative at 190 μg/disc, but positive at higher concentrations. 
i Without metabolic activation. 
j Calculated using relative molecular mass of 2-furyl methyl ketone = 110.11. 
k Positive only in strain TA98 with an increase in the presence of metabolic activation. 
l Negative at 550 μg/disc; positive at 5500 and 55 000 μg/disc (with and without metabolic activation). 
m Cytotoxicity was observed at 12 398 μg/ml (112.6 mmol/l) in the presence of metabolic activation. 
n Clastogenic activity increased with metabolic activation (statistical significance of results was not specified). 
o Cytotoxicity was observed at 3333 μg/plate in all S. typhimurium strains and at 2166 μg/plate inS. typhimurium strains TA100 and TA1537. 
p Cytotoxicity was observed at the 3330 μg/plate level in all S. typhimurium strains and at 1000 μg/plate in S. typhimurium strains TA100 and TA1535. 
q Cytotoxicity was observed at 3330 μg/plate in the absence of metabolic activation. 
r 3-h continuous exposure time. 
s 24-h continuous exposure time. 
t 48-h continuous exposure time. 
u With metabolic activation. 
v Statistically significant dose-dependent increases in chromosomal aberrations were seen at the two highest concentrations only, 325 and 375 μg/ml. 
w Mice received 2-methylfuran in the diet for 5 consecutive days at 24-h intervals. 
x Two experimental protocols were utilized. In one experiment, animals received single oral dose administrations of the test compound. In the other 
experiment, the test compound was orally administered once per day at the same concentrations as in the single-dose study for 5 consecutive days 
with 24-h intervals between doses. 
y No effects observed at 20 mg/kg bw dose level and only mild, but significant (P < 0.05) effects seen at higher concentrations in bone marrow cells. 
z Chromosomal aberrations were observed in the presence of significant mitodepression. 
aa A single statistically significant occurrence of increased chromosomal aberrations observed 3 weeks following a single dose administration in the 
60 mg/kg bw test group; statistically significant increases in polyploidy and XY univalents observed at weeks 3 and 4 at 60 mg/kg bw in multipledose- 
treated rats. 
bb Single dose administered by gavage. 
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Substances listed in brackets are the JECFA evaluated supporting substances in FGE.13Rev2 
TABLE 2.2: GENOTOXICITY (IN VITRO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H) 
Chemical Name [FL-no:] Test system Test Object  Concentration Result  Reference  Comments 
(Furfuryl alcohol [13.019]) Ames test  S. typhimurium TA98, TA100, TA1535 and 
TA1537  
 294 µg/plate  Negative1   (Florin et al., 1980)  
Ames test  S. typhimurium TA98, TA100, TA1535 and 
TA1537 
10000 µg/plate  Negative1 (Mortelmans et al., 1986) 
(NTP, 1999a) 
 
Ames test  S. typhimurium TA100  2500 - 12500 µg/ml  Negative1 (Stich et al., 1981a)  
Ames test  S. typhimurium TA98, TA100 and TA102  198000 µg/plate  Negative1 (Aeschbacher et al., 1989)  
Ames test  S. typhimurium TA98 and TA100  81 - 323 µg/plate  Negative1 (Shinohara et al., 1986)  
Modified Ames test  S. typhimurium TA1535, TA100 and TA1537  200000 µg/ml  Positive1 (McGregor et al., 1981)  
Rec assay  B. subtilis  2000 - 20000 µg/disk  Positive1 (Shinohara et al., 1986)  
Sister chromatid exchange  CHO cells  245 µg/ml  Positive1 (Stich et al., 1981a)  
Sister chromatid exchange  CHO cells  500 µg/ml  Positive/weakly 
positive2  
Negative3 
(NTP, 1999a)  
Sister chromatid exchange  Human Lymphocytes  Up to 196 µg/ml  Negative  (Jansson et al., 1986)  
Sister chromatid exchange  Human  
Lymphocytes  
Up to 970 µg/ml  Negative  (Gomez-Arroyo and 
Souza, 1985) 
 
Chromosomal aberration  CHO cells  2000 µg/ml  Positive  (Stich et al., 1981a)  
Chromosomal aberration  CHO cells  1600 µg/ml  Negative1 (NTP, 1999a)  
SHE test  Syrian hamster embryo cells  NR Negative3  (Kerckaert et al., 1996)  
Gene Conversion Assay  S. cerevisiae strain D7  13500 - 16000 µg/ml  Positive2 (Stich et al., 1981b)  
Mammalian cell assay  Mouse embryo fibroblast cells (T1) 10 µg/ml  Negative2 (Kowalski et al., 2001)  
p53 – induction assay  Mouse embryo fibroblast cells (NCTC 929)  50 µg/ml  Negative2  (Duerksen-Hughes et al., 
1999) 
 
(Furfuryl acetate [13.128]) Ames test  S. typhimurium TA1535, TA98 and TA100  33 - 666 µg/plate  Positive2  (Mortelmans et al., 1986)  
(Furfural [13.018]) Ames test  S. typhimurium TA 1535, TA100, TA1537, 
TA1538, TA98  
0.1 - 1000 µg/ml  Negative1 (McMahon et al., 1979)  
Ames test  S. typhimurium TA100, TA98 and TA1535  Up to 3460 µg/plate  
5766 µg/plate  
Negative1  
Positive2 (weak)  
(Loquet et al., 1981)  
Ames test  S. typhimurium TA100, TA98 and TA102  Up to 115320 µg/plate  Negative1  (Aeschbacher et al., 1989)  
Ames test  S. typhimurium TA100 and TA98  15 - 63 µg/plate  Negative1 (Shinohara et al., 1986)  
Ames test  S. typhimurium TA104 5 - 500 µg/plate  Positive3 (Shane et al., 1988)  
Ames test  S. typhimurium TA100 and TA102  5 - 500 µg/plate  Negative3 (Shane et al., 1988)  
Ames test  S. typhimurium TA104 and TA102 96 µg/plate  Negative  (Marnett et al., 1985a)  
Ames test  S. typhimurium TA98, TA100 and TA1535  Up to 6667 µg/plate  Negative1 (Mortelmans et al., 1986)  
Ames test  S.typhimurium TA98, TA100  Up to 1000 µg  Negative2  (Osawa and Namiki, 1982)  
Ames test  S.typhimurium TA98, TA100, TA1535, TA1537  33 - 6666 µg/plate  Negative1  
TA100 equivocal2  
(NTP, 1990a)  
Ames test  S. typhimurium TA100  8000 µg/plate  Positive1 (Zdzienicka et al., 1978)  
Ames test  S. typhimurium TA98  8000 µg/plate  Negative1  (Zdzienicka et al., 1978)  
Ames test  S. typhimurium TA100, TA102  100 - 10000 µg/plate  Negative2 (Dillon et al., 1998)  
Ames test  S. typhimurium TA104  100 - 10000 µg/plate  Equivocal2 (Dillon et al., 1998)  
Ames test  S. typhimurium TA102, TA104  100 - 10000 µg/plate  Negative3 (Dillon et al., 1998)  
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TABLE 2.2: GENOTOXICITY (IN VITRO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H) 
Chemical Name [FL-no:] Test system Test Object  Concentration Result  Reference  Comments 
Ames test  S. typhimurium TA100  100 - 10000 µg/plate  Equivocal3 (Dillon et al., 1998)  
Modified Ames test  S. typhimurium TA100  426 µg/plate  Negative  (Kim et al., 1987b)  
Modified Ames test  S. typhimurium TA100, TA1535 and TA1537  200000 µg/ml  Negative  (McGregor et al., 1981)  
Modified Ames test  E. coli WP2 and WP2 uvrA  0.1 - 1000 µg/ml  Negative1 (McMahon et al., 1979)  
SOS induction  S.typhimurium TA1535/ pSK1002  1932 µg/ml  Negative1 (Nakamura et al., 1987)  
Rec-assay  B. subtilis H17 & M45  Up to 1000 µg  Negative  (Osawa and Namiki, 1982)  
Rec-assay  B. subtilis H17 & M45  0.6 ml  Negative1 (Matsui et al., 1989)  
Rec-assay  B. subtilis strains H17 & M45  1700 - 17000 µg/disk  Positive1 (Shinohara et al., 1986)  
Forward mutation assay  L5178Y tk+/- Mouse Lymphoma Cells  25 - 100 µg/ml  
200 µg/ml  
Negative2  
Positive2  
(McGregor et al., 1988b)   
Sister chromatid exchange  CHO cells  2500 - 4000 µg/ml  Positive1  (Stich et al., 1981a)  
Sister chromatid exchange  CHO cells  Up to 1170 µg/ml  Positive1 (NTP, 1990a)   
Sister chromatid exchange  Human  
Lymphocytes  
Up to 0.035 mM4  
0.07 - 0.14 Mm4  
Negative1  
Positive1  
(Gomez-Arroyo and 
Souza, 1985)  
 
Chromosomal aberration  CHO cells  500 µg/ml  
1000 - 2000 µg/ml  
Negative  
Positive  
(Nishi et al., 1989)  
Chromosomal aberration  CHO cells  Up to 40 mM (3,840 mg)  Positive1 (Stich et al., 1981a)  
Chromosomal aberration  CHO cells  3000 µg/ml  Positive  (Stich et al., 1981b)  
Chromosomal aberration  CHO cells  375 µg/ml2  
750 µg/ml3  
Positive  (Gudi and Schadly, 1996)  
Chromosomal aberration  CHO cells  Up to 1,230 µg/ml  Positive1 (NTP, 1990a)   
Unscheduled DNA 
Synthesis  
Human liver slices  0.005 - 10 mM  Negative (Adams et al., 1998b)  
DNA-protein cross-links  EBV- human Burkitt’s lymphoma cells  25 mM Positive5 (Costa et al., 1997)  
5-Hydroxymethyl-
furfuraldehyde [13.139] 
Ames test  S. typhimurium TA98; TA100  0.2 - 1 μmol/plate  Negative  (Surh et al., 1994) The study is considered 
valid. Purity 99 %. 
Ames test  S. typhimurium TA98; TA100  0.2 - 2.0 µg/plate  Positive3  (Omura et al., 1983) Positive dose related 
respons inTA100 only, 
most potent without S9. 
Purity and other 
experimental details not 
reported. The validity of 
the study can not be 
evaluated. 
Ames test  S. typhimurium TA98; TA100  0.17 -  0.66 µmol/plate Positive3  (Shinohara et al., 1986) Positive results only 
obtained in TA100 with 
S9. Reverse dose-
respons relationship. 
Experimental details are 
lacking.  
Ames test  S. typhimurium TA104  0.1 - 0.8 mM  Negative2  
Positive 
(Lee et al., 1995b) Positive result was 
obtained by inclusion of 
PAPS and the rat liver 
cytosol in the assay. The 
study is considered valid. 
Ames test  S. typhimurium TA98; TA100;  1 - 50 µl/plate3  Negative1 (Aeschbacher et al., 1981) The study is considered 
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TABLE 2.2: GENOTOXICITY (IN VITRO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H) 
Chemical Name [FL-no:] Test system Test Object  Concentration Result  Reference  Comments 
valid. 
Ames test  S. typhimurium TA100  4.44 µM/plate  Negative2  (Kim et al., 1987b) Single dose only. 
Ames test  S. typhimurium TA98; TA100; TA1535; TA1537  3 µmol/plate Negative1  (Florin et al., 1980) Spot test. The study is 
considered valid. 
Ames test  S. typhimurium TA100  10 µg/plate  Negative2  (Majeska and McGregor, 
1992) 
The study is considered 
valid. 
Ames test S. typhimurium TA97, TA98, TA102, TA1535 100 - 10,000 µg/plate Negative1 (NTP, 2010c)  
Ames test S. typhimurium TA100 100 - 10,000 µg/plate Weakly positive2 (NTP, 2010c)  
Ames test S. typhimurium TA100 and TA98 1,500 - 10,000 µg/plate Negative1 (NTP, 2010c)  
Ames test S. typhimurium TA98, TA100, TA1535, TA1537 At 0.5 µg/mL up to 5000 µg/mL Negative1 (Severin et al., 2010)  
Reverse mutation assay E. coli WP2 uvrA/pKM101 1,500 - 10,000 µg/plate Negative1 (NTP, 2010c)  
Micronucleus assay HepG2 cells 0, 5.35, 7.87, 11.57, 17, 25, 36.6 mM Negative28 (Severin et al., 2010)  
SCE induction V79-hCYP2E1-hSULT1A1 cells 19.8 - 3808 µM Positive (Glatt et al., 2005)  
SCE induction V79-Mz cells 238 - 3808 µM, Positive29  (Glatt et al., 2005)  
Umu assay  S. typhimurium  
TA1535  
20 mM Positive9  (Janzowski et al., 2000) Positive results were 
only obtained at high 
concentrations resulting 
in reduced cell viability 
and growth. The study is 
considered valid but 
interpretation of data is 
questionable. 
Rec assay  B. subtilis  
H 17 rec+; M 45 rec-  
0.25 - 12.5 mg/disk  Positive1  (Shinohara et al., 1986) Experimental details are 
lacking. The validity of 
the study can not be 
evaluated. 
Chromosomal aberration  Chinese hamster V79 cells  Up to 2000 µg/ml  Positive10  (Nishi et al., 1989) Weak positive response 
were only obtained at 
high concentrations. The 
study is considered valid. 
Comet assay  V79, Caco-2, primary human colon cells and 
primary rat hepatocytes  
Up to 80 mM  Negative2  (Janzowski et al., 2000) The study is considered 
valid but interpretation 
of data is questionable. 
Comet assay HepG2 cells 0, 5.35, 7.87, 11.57, 17, 25, 36.6 mM Positive27, 28 (Severin et al., 2010)  
Comet assay Human Caco-2 cells 3,153 - 12,611 µg/mL (25 - 100 mM) Positive25 (Durling et al., 2009)  
Comet assay Human HEK293 cells 3,153 - 12,611 µg/mL (25 - 100 mM) Positive25 (Durling et al., 2009)  
Comet assay Mouse lymphoma L5178Y cells 3,153 - 12,611 µg/mL (25 - 100 mM) Positive25 (Durling et al., 2009)  
Comet assay Chinese hamster V-79  cells 315 - 12,611 µg/mL (2.5 - 100 mM) Positive26 (Durling et al., 2009)  
Comet assay Chinese hamster V-79-hP-PST cells 315 - 12,611 µg/mL (2.5 - 100 mM) Positive26 (Durling et al., 2009)  
HPRT assay  V79 cells  Up to 140 mM  Positive1, 11  (Janzowski et al., 2000) Positive response were 
only obtained at high 
concentrations resulting 
in reduced cell viability 
and growth. The study is 
considered valid but 
interpretation of data is 
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TABLE 2.2: GENOTOXICITY (IN VITRO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H) 
Chemical Name [FL-no:] Test system Test Object  Concentration Result  Reference  Comments 
questionable. 
HPRT and tk assay  TK6 human lymphoblast cells  20 - 75 µg/ml  Negative  (Surh and Tannenbaum, 
1994)  
The study is considered 
valid. 
(5-Methylfurfural [13.001]) Ames test S. typhimurium TA1537, TA100 and TA1535  288 µg/plate  Negative1 (Florin et al., 1980)  
Ames test  S. typhimurium TA98, TA100 and TA102  96100 µg/plate  Negative1 (Aeschbacher et al., 1989)  
Ames test  S. typhimurium TA98 and TA100  79 - 316 µg/plate  Negative1 (Shinohara et al., 1986)  
Rec-assay  B. subtilis strains H17 & M45  0.55 - 5500 µg/disk  Positive1 (Shinohara et al., 1986)  
Sister chromatid exchange  CHO cells  2200 - 4070 µg/ml  Positive1 (Stich et al., 1981a)  
2-Furoic acid [13.136] Ames test  S. typhimurium TA98; TA100  25 - 100 µg/plate  Negative2 (Ichikawa et al., 1986b) The study is considered 
valid. 
Ames test  S. typhimurium TA100   Negative  (Soska et al., 1981) Dose not reported. The 
validity of the study can 
not be evaluated. 
Ames test  S. typhimurium TA100  1000 µg/plate  Negative  (Kitamura et al., 1978) The study is considered 
valid. 
DNA repair test  E. coli  
WP2l WP2 uvrA; WP67; WP100; CM 561; CM 
571; CM 611  
1000 µg/disk  Negative  (Soska et al., 1981) The study is considered 
valid. 
Unscheduled DNA synthesis  Primary rat hepatocytes  1000 µg/ml  Negative10, 12  (Aaron et al., 1989) Study performed in 
accordance with GLP. 
The study is considered 
valid. 
(Methyl-2-furoate [13.002]) Ames test  S. typhimurium TA98; TA100  100 µg/plate  Negative10  (Ichikawa et al., 1986b)  
(2-Acetylfuran [13.054]) 
  
UDS  Human hepatocytes  2.19, 4.38, 8.75, 17.5, 35, 70, 140 or 
280 µg/ml  
Negative  (Durward, 2007a)  New study submitted to 
JECFA for the 69th 
meeting. 
Reverse mutation  S. typhimurium TA98 and TA100  0.165, 0.330, 0.495 or 0.660 
µmol/plate (13.5, 27.1, 40.6 or 54.2 
µg/plate)20  
Negative/positive1,21  (Shinohara et al., 1986) Study reported by 
JECFA at the 65th 
meeting. 
DNA damage  E. coli PQ37 (SOS  chromotest)  Not specified  Slightly positive  (Eder et al., 1993) Study reported by 
JECFA at the 65th 
meeting. 
DNA damage  B. subtilis H17 (rec+) and M45 (rec-)  550, 5500 or 55000 µg/disc  Negative/ positive1,22  (Shinohara et al., 1986) Study reported by 
JECFA at the 65th 
meeting. 
Chromosomal aberration CHO cells 0 - 112.6 mmol/l  
(0 - 13220 µg/ml)20   
Positive22,23,24 (Stich et al., 1981b) Study reported by 
JECFA at the 65th 
meeting. 
(2-Methylfuran  [13.030]) 
  
Reverse mutation   S .typhimurium  TA98 and TA100  0.165, 0.330, 0.495 or 0.660 
µmol/plate (13.5, 27.1, 40.6 or 54.2 
µg/plate)13  
Negative1   (Shinohara et al., 1986)  Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation   S. typhimurium TA98,  TA100, TA102 and 
TA1535  
Up to 10 000 µg/plate   Negative1,14,15  (Zeiger et al., 1992)  Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation   S. typhimurium TA97 and  TA104  Up to 10 000 µg/plate   Equivocal1,14,15  (Zeiger et al., 1992)  Study reported by 
JECFA at the 65th 
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TABLE 2.2: GENOTOXICITY (IN VITRO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H) 
Chemical Name [FL-no:] Test system Test Object  Concentration Result  Reference  Comments 
meeting. 
Reverse mutation   S. typhimurium TA98,  TA100 and TA102 11 nmol/plate to 1,1 mmol/ plate (0,9 
-90 310 µg/plate)13   
Negative1   (Aeschbacher et al., 1989)  Study reported by 
JECFA at the 65th 
meeting. 
DNA damage   Bacillus subtilis H17 (rec+) and M45 (rec˜Ñ)   0.16, 16 or 1600 µg/disc   Negative/positive1,16 (Shinohara et al., 1986)  Study reported by 
JECFA at the 65th 
meeting. 
Chromosomal aberration  CHO cells   0 - 150 mmol/l   
(0 - 12315 µg/ml)13  
Positive1,17   (Stich et al., 1981b) Study reported by 
JECFA at the 65th 
meeting. 
(2,5-Dimethylfuran  [13.029]) 
  
Reverse mutation  S. typhimurium TA98 and  TA100   0.165, 0.330, 0.495 or 0.660 
µmol/plate (13.5, 27.1, 40.6 or 54.2 
µg/plate)18  
Negative1   (Shinohara et al., 1986) Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation   S. typhimurium TA98  and TA100  Not specified   Negative1   (Lee et al., 1994a) Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation   S. typhimurium TA97,  TA98, TA100 and 
TA1535   
Up to 3333 µg/plate   Negative1,14,15 (Zeiger et al., 1992) Study reported by 
JECFA at the 65th 
meeting. 
DNA damage   B. subtilis H17 (rec+)  and M45 (rec-)  190, 1900 or 9500 µg/disc   Negative/positive1,19   (Shinohara et al., 1986) Study reported by 
JECFA at the 65th 
meeting. 
Chromosomal aberration Chinese hamster V79  cells 1 mmol/l (96.13 µg/ml)18   Negative  (Ochi and Ohsawa, 1985) Study reported by 
JECFA at the 65th 
meeting. 
Chromosomal aberration CHO cells  0 - 20 mmol/l  (0 - 1923 µg/ml)18   Positive1,17   (Stich et al., 1981b) Study reported by 
JECFA at the 65th 
meeting. 
NR=Not Reported 
1With and without S9 metabolic activation.  
2 Without S9 metabolic activation.  
3 With S9 metabolic activation. 
4 Concentration that was added to the culture. 
5 Significant increases in % DNA-protein cross-links occurred only when cell viability was 40 % or less (i.e. high incidence of cell death). 
6 TA98 with S9 metabolic activation; TA100 without S9 metabolic activation. 
7 5-Hydroxymethylfurfuraldehyde with 0.05 mol L-tryptophan without the presence of nitrite treatment.  
8 5-Hydroxymethylfurfuraldehyde with 0.05 mol L-tryptophan treated with nitrite.  
9 At concentrations of 12 mmol and greater, positive results were obtained without S9 metabolic activation. The dose dependent results were noted at concentrations known to be cytotoxic.  
10 Metabolic activation not reported.  
11 Effects occurred at concentrations inhibiting cellular growth. 
12 Dose levels above 300 microgram/ml were cytotoxic.  
13 Calculated using relative molecular mass of 2-methylfuran = 82.1. 
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14 Preincubation method. 
15 Occasional incidences of slight to complete clearing of the background lawn at the higher concentrations. 
16 Negative at all concentrations with metabolic activation; positive without metabolic activation. 
17 Clastogenic activity decreased with metabolic activation (statistical significance of results was not specified). 
18 Calculated using relative molecular mass of 2,5-dimethylfuran = 96.13. 
19 Positive at every concentration without metabolic activation; with metabolic activation, negative at 190 μg/disc, but positive at higher concentrations. 
20 Calculated using relative molecular mass of 2-furyl methyl ketone = 110.11. 
21 Positive only in strain TA98 with an increase in the presence of metabolic activation. 
22 Negative at 550 μg/disc; positive at 5500 and 55 000 μg/disc (with and without metabolic activation). 
23 Cytotoxicity was observed at 12 398 μg/ml (112.6 mmol/l) in the presence of metabolic activation. 
24 Clastogenic activity increased with metabolic activation (statistical significance of results was not specified). 
25 Positive only at the highest concentration tested with significant decrease in cell viability. 
26 Positive at high concentration with significantly reduced cell viability. 
27Cytotoxic at the two highest doses. 
28 20 hours of exposure. 
29Weakly positive but statistically significant at each concentration. 
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Substances listed in brackets are the JECFA evaluated supporting substances in FGE.13Rev2 
TABLE 2.3: GENOTOXICITY (IN VIVO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H) 
Chemical Name [FL-no:] Test system Test Object Route Dose Result Reference Comments 
(Furfuryl alcohol [13.019]) Sex-linked recessive lethal 
test  
Drosophila 
melanogaster  
Injection Up to 6500 ppm  Negative  (Rodriquez-Arnaiz et al., 1989)  
Sister chromatid exchange  Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
32300 mg/m3  Negative (Gomez-Arroyo and Souza, 1985)  
Chromosomal aberration 
assay  
Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
32300 mg/m3  Negative (Gomez-Arroyo and Souza, 1985)  
Chromosomal aberration 
assay  
Mouse bone 
marrow cells 
Drinking water 0.5 mg/kg  
1 - 2 mg/kg  
Negative  
Positive  
(Sujatha and Subramanyam, 1994)  
Sister chromatid exchange  Mouse bone 
marrow cells  
IP injection 300 mg/kg  Negative (NTP, 1999a)  
Chromosomal aberration 
assay  
Mouse bone 
marrow cells  
IP injection 300 mg/kg  Negative  (NTP, 1999a)  
Micronucleus assay  Mouse bone 
marrow cells 
IP injection 250 mg/kg  Negative  (NTP, 1999a)  
Mouse bioassay  Tg·AC transgenic 
mice  
Dermal exposure 1.5 mg; 5 day/week for 20 weeks  Negative (Spalding et al., 2000)  
(Furfural [13.018]) 
 
Sex-linked recessive lethal 
test  
Drosophila 
melanogaster  
Diet 1000 ppm  Negative  (Woodruff et al., 1985)  
Sex-linked recessive lethal 
test  
Drosophila 
melanogaster 
Injection 100 ppm  Positive (Woodruff et al., 1985)  
Sex-linked recessive lethal 
test  
Drosophila 
melanogaster 
Injection Up to 6500 ppm  Negative (Rodriquez-Arnaiz et al., 1989)  
Chromosome Loss  Drosophila 
melanogaster 
Oral or injected 3750 - 5000 ppm. Mated with repair-
proficient females  
Negative  (Rodriquez-Arnaiz et al., 1992)  
Chromosome Loss  Drosophila 
melanogaster 
Oral or injected 3750 - 5000 ppm. Mated with repair-
deficient females  
Positive (Rodriquez-Arnaiz et al., 1992)  
Reciprocal translocations  Drosophila 
melanogaster 
Injection 100 ppm  Negative (Woodruff et al., 1985)  
Nondisjunction assay  Drosophila 
melanogaster 
(females)  
Inhalation 1.5 %  Negative1  (Muñoz and Barnett, 1999)  
Sister chromatid exchange  Mouse bone 
marrow cells  
Injection 50 - 200 mg/kg  Negative (NTP, 1990a)   
Sperm head abnormalities  Mouse Oral 4000 ppm daily for 5 weeks  Negative (Subramanyam et al., 1989)  
Somatic chromosome 
mutations  
Swiss albino 
mouse (bone 
marrow cells)  
 1000 - 2000 ppm  
4000 ppm for 5 days  
Negative  
Positive  
(Subramanyam et al., 1989)  
Sister chromatid exchange  Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
9454 mg/m3 Negative (Gomez-Arroyo and Souza, 1985)  
Chromosomal aberration 
assay  
Adult Human 
Lymphocytes  
Inhalation 
(occupational 
9454 mg/m3 Negative (Gomez-Arroyo and Souza, 1985)  
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TABLE 2.3: GENOTOXICITY (IN VIVO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H) 
Chemical Name [FL-no:] Test system Test Object Route Dose Result Reference Comments 
atmosphere) 
Unscheduled DNA synthesis  Mouse  Oral 50 - 320 mg/kg Negative (Edwards, 1999)  
Unscheduled DNA synthesis  F344 Rat  Oral 5 - 50 mg/kg Negative (Phillips et al., 1997)  
Gene mutation in the λlacZ-
gene in liver 
Transgenic mouse  
CD2F1 (BALB/c x 
DBA/2) 
Oral 75 - 300 mg/kg Negative (CIVO-TNO, 2003)  
(2-Furyl methyl ketone [13.054]) SCE   Mouse bone 
marrow   
 1000, 2000 or 3000  mg/l (20, 40 or 
60 mg)kg bw)2   
Positive   (Sujatha, 2007)   New study submitted to 
JECFA for the 69th 
meeting. 
UDS   Rat liver    7 or 21 mg/kg bw   Negative   (Durward, 2007b)   New study submitted to 
JECFA for the 69th 
meeting. 
Chromosomal aberration Mouse bone 
marrow 
 1000, 2000 or 3000  mg/l (20, 40 or 
60 mg/ kg bw)2   
Positive3,4 (Sujatha et al., 1993) Study reported by 
JECFA at the 65th 
meeting. 
Chromosomal aberration Mouse 
spermatocytes 
  1000, 2000 or 3000  mg/l (20, 40 or 
60 mg/kg bw)2   
Negative5 (Sujatha et al., 1993) Study reported by 
JECFA at the 65th 
meeting. 
(2-Methylfuran  [13.030]) Chromosomal aberration Mouse bone 
marrow  cells and 
spermatocytes 
 1000, 2000 or 4000 mg/kg (100, 200 
or 400 mg/kg bw per day)6   
Negative (Subramanyam et al., 1989) Study reported by 
JECFA at the 65th 
meeting. 
5-Hydroxymethylfurfural [13.139] Micronucleus assay Mouse peripheral 
blood cells 
 47, 94, 188, 375 or 750 mg/kg bw/day Negative (NTP, 2010c)  
1 Exposure to 1 % solutions did not affect the flies’ behaviour and they had a 95 % survival rate. At dose concentrations of 1.3 and 1.5 % the results indicate a threshold for the induction of nondisjunction.  
2 Two experimental protocols were utilized. In one experiment, animals received single oral dose administrations of the test compound. In the other 
experiment, the test compound was orally administered once per day at the same concentrations as in the single-dose study for 5 consecutive days 
with 24-h intervals between doses. 
3 No effects observed at 20 mg/kg bw dose level and only mild, but significant (P < 0.05) effects seen at higher concentrations in bone marrow cells. 
4 Chromosomal aberrations were observed in the presence of significant mitodepression. 
5 A single statistically significant occurrence of increased chromosomal aberrations observed 3 weeks following a single dose administration in the 
60 mg/kg bw test group; statistically significant increases in polyploidy and XY univalents observed at weeks 3 and 4 at 60 mg/kg bw in multipledose-treated rats. 
6 Mice received 2-methylfuran in the diet for 5 consecutive days at 24 hours intervals. 
 
 
 
 
 
TABLE 2.4: GENOTOXICITY FGE.65 
No genotoxicity data available for the sulphur containing furan-derivatives 
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TABLE 2.5: SUMMARY OF GENOTOXICITY DATA OF FURFURYL DERIVATIVES EVALUATED BY JECFA (JECFA, 2001B) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
13.019 
451 
Furfuryl alcohol 
  
O
OH
 
Reverse mutation  S. typhimurium TA98, TA100, TA1535, 
TA1537 
294 µg/plate Negativea,b (Florin et al., 1980) 
Reverse mutation S. typhimurium TA98, TA100, TA1535 Up to10 000 µg/plate Negativea,b (Mortelmans et al., 1986) 
Reverse mutation S. typhimurium TA100 2500 - 12 500µg/ml  Negativea,b (Stich et al., 1981a) 
Reverse mutation S. typhimurium TA98, TA100, TA102 Up to 198 000 µg/plate Negativea,b (Aeschbacher et al., 1989) 
Reverse mutation S. typhimurium TA98, TA100 81 - 323 µg/plate Negativea,b (Shinohara et al., 1986) 
Reverse mutation  k TA1535, TA100, TA1537 (modified 
assay) 
200 000 µg/ml Positivea,b (McGregor et al., 1981) 
DNA repair and H17 (rec+) k M45 (rec–) µg/disc 2000–20 000  Positivea,b (Shinohara et al., 1986) 
Sister chromatid exchange  Chinese hamster ovary cells 245 µg/ml Positivea,b (Stich et al., 1981b) 
Sister chomatid exchange Human lymphocytes Up to 196 µg/ml Negative (Jansson et al., 1986) 
Siser chromatid exchange Human lymphocytes Up to 970 µg/ml Negative (Gomez-Arroyo and Souza, 
1985) 
Chromosomal aberration Chinese hamster ovary cells 2000 µg/ml Positive (Stich et al., 1981b) 
Gene conversion  S. cerevisiae strain D7 13 500 - 16 000 µg/ml Positivea (Stich et al., 1981a) 
Sex-linked recessive l lethal mutation D. melanogaster Up to 6500 ppm by injection Negative (Rodriquez-Arnaiz et al., 
1989) 
Sister chromatid exchange Adult human lymphocytes 32 300 mg/m3 in occupational 
atmosphere 
Negative (Gomez-Arroyo and Souza, 
1985) 
Sister chomatid exchange Adult human lymphocytes 32 300 mg/m3 in occupational 
atmosphere 
Negative (Gomez-Arroyo and Souza, 
1985) 
Chromosomal aberration 
  
Mouse bone-marrow cells  
  
0.5 mg/kg bw in drinking-water 
1 - 2 mg/kg bw in drinking-water 
Negative 
Positive 
(Sujatha and Subramanyam, 
1994) 
  
13.128 
739 
Furfuryl acetate O
O
O
 
 
Reverse mutation S. typhimurium TA1535, TA98, TA100 33 - 666 µg/plate Positivea,b (Mortelmans et al., 1986) 
13.018 
450 
Furfural O
O
 
 
Reverse mutation S. typhimurium TA 1535, TA100, 
TA1537, TA1538, TA98 
0.1 - 1000 µg/ml Negativea,b (McMahon et al., 1979) 
Reverse mutation S. typhimurium TA100, TA98, TA1535 Up to 3460 µg/plate  
5766 µg/plate 
Negativea,b 
Positivea 
(weakly) 
(Loquet et al., 1981) 
Reverse mutation S. typhimurium TA100, TA98, TA102 Up to 115 320 µg/plate Negativea,b (Aeschbacher et al., 1989) 
Reverse mutation S. typhimurium TA100, TA98 15 - 63 µg/plate Negativea,b (Shinohara et al., 1986) 
Reverse mutation S. typhimurium TA104 5 - 500 µg/plate Positiveb (Shane et al., 1988) 
Reverse mutation S. typhimurium TA100, TA102  5 - 500 µg/plate Negativeb (Shane et al., 1988) 
Reverse mutation S. typhimurium TA104, TA102 96 µg/plate Negative (Marnett et al., 1985a) 
Reverse mutation S. typhimurium TA98, TA100, TA1535 Up to 6667 µg/plate Negativea,b (Mortelmans et al., 1986) 
Reverse mutation S. typhimurium TA98, TA100 Up to 1000 µg Negativea (Osawa and Namiki, 1982) 
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TABLE 2.5: SUMMARY OF GENOTOXICITY DATA OF FURFURYL DERIVATIVES EVALUATED BY JECFA (JECFA, 2001B) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
Reverse mutation S. typhimurium TA98, TA100, TA1535, 
TA1537  
33– 6666 µg/plate Negativea,b  
Equivocal in 
TA100a 
(NTP, 1990a) 
Reverse mutation S. typhimurium TA100  8000 µg/plate Positivea,b (Zdzienicka et al., 1978) 
Reverse mutation  S. typhimurium TA98 8000 µg/plate Negativea,b (Zdzienicka et al., 1978) 
Reverse mutation S. typhimurium TA100, TA102 1 00 - 10 000 µg/plate Negativea (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA104 100 - 10 000 µg/plate Equivocala (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA102, TA104 100 - 10 000 µg/plate Negativeb (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA100 10010 000 µg/plate Equivocalb (Dillon et al., 1998) 
Reverse mutation S. typhimurium TA100 (modified assay) 426 µg/plate Negativea,b (Kim et al., 1987b) 
Reverse mutation S. typhimurium TA100, TA1535, 
TA1537 (modified assay) 
200 000 µg/ml Negative (McGregor et al., 1981) 
Reverse mutation E. coli WP2, WP2 uvrA (modified 
assay) 
0.1- 1000 µg/ml Negativea,b (McMahon et al., 1979) 
SOS induction  S. typhimurium TA1535/ pSK1002 1932 µg/ml Negativea,b (Nakamura et al., 1987) 
DNA repair B. subtilis H17 (rec+) and M45 (rec–) Up to 1000 µg Negativea (Osawa and Namiki, 1982) 
DNA repair B. subtilis H17 (rec+) and M45 (rec–) 0.6 ml Negativea,b (Matsui et al., 1989) 
DNA repair B. subtilis H17 (rec+) and M45 (rec–) 1700 - 17 000 µg/disc Positivea,b (Shinohara et al., 1986) 
Forward mutation L5178Y mouse lymphoma cells, Tk+/– 
locus 
25 - 100 µg/ml 
200 µg/ml 
Negativea 
Positivea 
(McGregor et al., 1988b) 
Sister chromatid exchange Chinese hamster ovary cells 2500 - 4000 µg/ml Positivea,b (Stich et al., 1981b) 
Sister chromatid exchange Chinese hamster ovary cells Up to 1170 µg/ml Positivea,b (NTP, 1990a) 
Sister chromatid exchange Human lymphocytes Up to 0.035 mmol/La 
0.07 -  0.14 mmol/Lc 
Negativea,b 
Positivea,b 
(Gomez-Arroyo and Souza, 
1985) 
Chromosomal aberration Chinese hamster ovary cells 500 µg/ml 
1000 - 2000 µg/ml 
Negative 
Positive 
(Nishi et al., 1989) 
Chromosomal aberration Chinese hamster ovary cells Up to 40 mmol/L  
(3840 mg) 
Positivea,b (Stich et al., 1981b) 
Chromosomal aberration Chinese hamster ovary cells 3000 µg/ml Positive (Stich et al., 1981a) 
Chromosomal aberration Chinese hamster ovary cells Up to 1230 µg/ml Positivea,b (NTP, 1990a) 
Unscheduled DNA synthesis Human liver slices 0.005 - 10 mmol/L  Negative (Adams et al., 1998b) 
Sex-linked recessive lethal mutation D. melanogaster 1000 mg/kg of diet Negative (Woodruff et al., 1985) 
Sex-linked recessive lethal mutation D. melanogaster 100 mg/kg by injection Positive (Woodruff et al., 1985) 
Sex-linked recessive lethal mutation D. melanogaster Up to 6500 mg/kg by injection Negative (Rodriquez-Arnaiz et al., 
1989) 
Chromosomal loss D. melanogaster Oral or injected dose of 3750 - 
5000 mg/kg of diet. Mated with 
repair-proficient females 
Negative (Rodriquez-Arnaiz et al., 
1992) 
Chromosomal loss D. melanogaster Oral or injected dose of 3750 - 
5000 mg/kg of diet. Mated with 
repair-deficient females 
Positive (Rodriquez-Arnaiz et al., 
1992) 
Reciprocal trans- location D. melanogaster 100 mg/kg by injection Negative (Woodruff et al., 1985) 
Sister chromatid exchange Mouse bone-marrow cells 50 - 200 mg/kg bw by injection Negative (NTP, 1990a) 
Spermhead abnormalities Mice 4000 mg/kg of diet daily for 5 Negative (Subramanyam et al., 1989) 
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TABLE 2.5: SUMMARY OF GENOTOXICITY DATA OF FURFURYL DERIVATIVES EVALUATED BY JECFA (JECFA, 2001B) 
FL-no 
JECFA-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
weeks 
Somatic chromo-somal mutation  Swiss albino mouse bone- marrow cells 1000 - 2000 mg/kg of diet Negative (Subramanyam et al., 1989) 
    4000 mg/kg bw for 5 days Positive   
Sister chromatid exchange Adult human lymphocytes 9454 mg/m3 in occupational 
atmosphere 
Negative (Gomez-Arroyo and Souza, 
1985) 
Chromosomal aberration Adult human lymphocytes 9454 mg/m3in occupational 
atmosphere 
Negative (Gomez-Arroyo and Souza, 
1985) 
Unscheduled DNA synthesis B6C3F1 mice  50 - 320 mg/kg bw orally Negative (Edwards, 1999) 
Unscheduled DNA synthesis Fischer 344 rats 5 - 50 mg/kg bw orally Negative (Phillips et al., 1997) 
13.001 
745 
5-Methylfurfural 
 
O
O
 
Reverse mutation S. typhimurium TA1537, TA100, 
TA1535 
288 µg/plate Negativea,b (Florin et al., 1980) 
Reverse mutation S. typhimurium TA98, TA100, TA102  96,100 µg/plate Negativea,b (Aeschbacher et al., 1989) 
Reverse mutation S. typhimurium TA98, TA100 79 - 316 µg/plate Negativea,b (Shinohara et al., 1986) 
DNA repair B. subtilis H17 (rec+) and M45 (rec–) 0.55 - 5500 µg/disk Positivea,b (Shinohara et al., 1986) 
Sister chromatid exchange Chinese hamster ovary cells 2200 - 4070 µg/ml Positivea,b (Stich et al., 1981b) 
a Without metabolic activation from a 9000  g supernatant of rat liver. 
b With metabolic activation. 
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TABLE 3: SUMMARY OF SAFETY EVALUATIONS 
 
Table 3.1: Summary of safety evaluation of 33 furan derivatives evaluated by JECFA (JECFA, 2001b) and considered in FGE.67Rev1 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
13.054 
1503 
2-Acetylfuran 
O
O 46 
13 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.059 
1491 
2-Pentylfuran O 0.18 
0.03 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.083 
1504 
2-Acetyl-5-methylfuran 
O
O 0.37 
0.1 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.101 
1505 
2-Acetyl-3,5-dimethylfuran 
O
O 0.0012 
0.002 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.105 
1507 
2-Butyrylfuran 
O
O 0.12 
0.2 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.163 
1509 
2-Pentanoylfuran 
O
O 0.061 
0.09 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.029 
1488 
2,5-Dimethylfuran O 0.012 
0.02 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.030 
1487 
2-Methylfuran O 0.21 
0.3 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.045 
1508 
1-(2-Furyl)-propan-2-one O
O
0.037 
0.02 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.052 
1520 
Furfuryl methyl ether O
O
0.024 
0.09 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
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Table 3.1: Summary of safety evaluation of 33 furan derivatives evaluated by JECFA (JECFA, 2001b) and considered in FGE.67Rev1 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
13.061 
1522 
Difurfuryl ether 
O
O
O 0.12 
0.09 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.069 
1492 
2-Heptylfuran O 0.012 
0.9 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.092 
1489 
2-Ethylfuran O 0.061 
0.5 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.103 
1490 
2-Butylfuran O 0.24 
0.5 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.106 
1493 
2-Decylfuran O 0.0012 
0.002 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.123 
1521 
Ethyl furfuryl ether O
O
0.0012 
0.002 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.138 
1510 
1-(2-Furyl)butan-3-one 
O
O 2.2 
3 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.148 
1494 
3-Methyl-2(3-methylbut-2-
enyl)furan O
0.12 
0.2 
Class II 
No evaluation 
 Additional genotoxicity 
data required 
 
13.031 
751 
2-Benzofurancarboxaldehyde OO
 
0.012 
0.01 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) Evaluted in FGE.219, No 
genotoxicity concern 
(EFSA, Nov 2007). No 
safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
Melting point to be 
provided. 
13.066 
1506 
3-Acetyl-2,5-dimethylfuran O
O
ND 
2 
Class III 
No evaluation 
 Additional genotoxicity 
data required 
 
13.070 
1512 
2-Hexanoylfuran 
O
O ND 
0.9 
Class III 
No evaluation 
 Additional genotoxicity 
data required 
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Table 3.1: Summary of safety evaluation of 33 furan derivatives evaluated by JECFA (JECFA, 2001b) and considered in FGE.67Rev1 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
13.191 
1526 
o-Ethyl S-(2-
furylmethyl)thiocarbonate O
S O
O 0.61 
0.9 
Class III 
No evaluation 
 Additional genotoxicity 
data required 
 
13.006 
1517 
Phenethyl 2-furoate 
O
O
O 0.012 
0.2 
Class III 
No evaluation 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.021 
1516 
Isopentyl 4-(2-furan)butyrate O O
O  
0.24 
0.09 
Class III 
No evaluation 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.022 
1513 
Ethyl 3(2-furyl)propionate 
O
O
O 0.012 
0.07 
Class III 
No evaluation 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.023 
1515 
Isopentyl 3-(2-furan)propionate 
O
O
O 0.24 
0.09 
Class III 
No evaluation 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.024 
1514 
Isobutyl 3-(2-furyl)propionate 
O
O
O 0.12 
24 
Class III 
No evaluation 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.047 
1518 
Propyl 3-(2-furyl)acrylate 
O
O
O 2.2 
1 
Class III 
No evaluation 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
Stereoisomeric composition 
to be specified. 
13.058 
1500 
3-(5-Methyl-2-furyl) butanal 
O
O
0.0012 
0.5 
Class III 
No evaluation 
 Additional data required. 
No adequate NOAEL exists 
 
13.074 
1495 
2,3-Dimethylbenzofuran 
O
0.52 
0.01 
Class III 
No evaluation 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.107 
1496 
2,4-Difurfurylfuran OO
O
0.0012 
0.002 
Class III 
No evaluation 
 Additional genotoxicity 
data required 
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Table 3.1: Summary of safety evaluation of 33 furan derivatives evaluated by JECFA (JECFA, 2001b) and considered in FGE.67Rev1 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
13.116 
1523 
2,5-Dimethyl-3-thioacetoxyfuran O
S
O
3.0 
4 
Class III 
No evaluation 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.190 
1525 
3-((2-Methyl3-furyl)thio)-2-
butanone 
O
S
O
0.012 
0.02 
Class III 
No evaluation 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
Racemate. 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
ND: not determined. 
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Table 3.2: Summary of Safety Evaluation Applying the Procedure for substances in FGE.13Rev2 (EFSA, 2011h) (based on intakes calculated by the MSDI 
approach) for FGE.13Rev2 (EFSA, 2011h) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation 
remarks 
13.122 
 
Ethyl 2-furoate O
O
O
0.39 
 
Class II 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.130 
759 
Furfuryl butyrate 
O
O
O 0.24 
 
Class II 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.136 
 
2-Furoic acid 
O
OH
O 0.013 
 
Class II 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.139 
 
5-
Hydroxymethylfurfuraldehyde 
O
OHO
 
0.39 
 
Class II 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.145 
 
Methyl 5-methylfurfuryl sulfide 
S
O
 
0.0024 
 
Class II 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.155 
 
2-Methyl-5-propionylfuran 
O
O 0.011 
 
Class II 
No evaluation 
  a) 
13.125 
 
2-Ethyl-5-methylfuran O 0.011 
 
Class II 
No evaluation 
  b) 
13.162 
 
2-Octylfuran O 0.011 
 
Class II 
No evaluation 
  b) 
13.011 
 
Ethyl furfuracrylate 
O
O
O 0.12 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.102 
 
Butyl 2-furoate O
O
O
0.12 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
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Table 3.2: Summary of Safety Evaluation Applying the Procedure for substances in FGE.13Rev2 (EFSA, 2011h) (based on intakes calculated by the MSDI 
approach) for FGE.13Rev2 (EFSA, 2011h) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation 
remarks 
13.108 
 
4,5-Dihydro-3-mercapto-2-
methylfuran 
O
SH
37 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.113 
 
2,5-Dimethyl-3-
(methyldithio)furan 
O
S
S
0.0012 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.114 
 
2,5-Dimethyl-3-
(methylthio)furan 
O
S
0.0024 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.124 
 
Ethyl furfuryl sulfide 
S
O 0.18 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.127 
 
Furfuryl 2-methylbutyrate 
O
O
O
0.73 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.129 
 
Furfuryl but-2-enoate O
O
O
0.11 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.132 
 
Furfuryl hexanoate O
O
O
0.58 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.133 
 
Furfuryl isobutyrate 
O
O
O
0.89 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.135 
 
1-(2-Furfurylthio)propanone O
S
O
0.61 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.141 
 
Methyl (2-furfurylthio)acetate O
S
O
O
0.011 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
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Table 3.2: Summary of Safety Evaluation Applying the Procedure for substances in FGE.13Rev2 (EFSA, 2011h) (based on intakes calculated by the MSDI 
approach) for FGE.13Rev2 (EFSA, 2011h) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), or 
8)] 
Evaluation 
remarks 
13.143 
 
Methyl 3-
(furfurylthio)propionate 
O
OS
O
0.011 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.144 
 
Methyl 5-methylfurfuryl 
disulfide 
O
S
S
 
0.0024 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.146 
 
Methyl furfuryl trisulfide 
S
S
S
O
 
0.0024 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.149 
 
5-Methyl-2-furanmethanethiol O
SH
 
0.37 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.178 
 
3-(Furfuryldithio)-2-
methylfuran 
O
O
S
S 0.24 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.185 
 
2-Furfuryl 3-oxo-2-butyl 
disulphide O
S
S
O 0.011 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.199 
 
3-[(2-Methyl-3-furyl)thio]-
butanal 
o
s O
1.2 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
a) Additional genotoxicity data required. 
b) Genotoxic in vitro. 
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Table 3.3: Summary of Safety Evaluation of 33 sulphur substituted furan derivatives (JECFA, 2002d) considered in FGE.65 (EFSA, 2009an) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
13.016 
1066 
bis-(2-Methyl-3-furyl) disulfide O
S
S
O
0.27 
0.7 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.026 
1072 
2-Furanmethanethiol O
SH
 
29 
11 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.050 
1081 
Difurfuryl disulfide 
S
SO
O
3.3 
0.7 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.053 
1076 
Methyl furfuryl sulfide 
S
O
 
0.97 
0.1 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.055 
1060 
2-Methylfuran-3-thiol O
SH  
0.52 
0.9 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
According to JECFA: Min. 
assay value is "95" and 
secondary components 
"Bis(2-methyl-3-
furyl)disulfide". 
13.064 
1078 
Methyl furfuryl disulfide 
S
SO
 
0.85 
0.04 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.152 
1061 
2-Methyl-3-(methylthio)furan O
S
1.2 
0.1 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.015 
1067 
bis-(2,5-Dimethyl-3-furyl) 
disulfide 
O
S
S
O
0.012 
0.7 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
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Table 3.3: Summary of Safety Evaluation of 33 sulphur substituted furan derivatives (JECFA, 2002d) considered in FGE.65 (EFSA, 2009an) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
13.017 
1068 
bis-(2-Methyl-3-furyl) 
tetrasulfide 
S
SS
S
O
O
0.97 
0.7 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.032 
1077 
Furfuryl isopropyl sulfide 
O
S
0.0012 
0.1 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.033 
1074 
S-Furfuryl acetothioate 
O
S
O 0.43 
0.05 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.040 
1071 
2,5-Dimethyl-3-thiofuroylfuran 
O
S
O
O
0.012 
0.01 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
JECFA evaluated (S)-2,5-
dimethyl-3-thiofuroylfuran 
(CASrn as in Register). 
Register CASrn refers to 
the (S)-enantiomer. 
13.041 
1070 
2,5-Dimethyl-3-
(isopentylthio)furan 
O
S
O
0.49 
0.7 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
Registername to be 
changed to 2,5-dimethyl-3-
(isovalerylthio)furan. 
13.051 
1073 
2-Furfuryl thioformate O
S O
 
1.3 
0.02 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.056 
1080 
Difurfuryl sulfide 
S
O
O
 
0.73 
0.005 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No adequate NOAEL exists, 
additional data required 
 
13.063 
1075 
S-Furfuryl propanethioate O
S
O
0.012 
0.005 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.065 
1062 
2-Methyl-5-(methylthio)furan O S
 
1.1 
0.02 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
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Table 3.3: Summary of Safety Evaluation of 33 sulphur substituted furan derivatives (JECFA, 2002d) considered in FGE.65 (EFSA, 2009an) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
13.071 
1063 
2,5-Dimethylfuran-3-thiol O
SH
0.024 
0.7 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.075 
1086 
2,6-Dimethyl-3-((2-methyl-3-
furyl)thio)heptan-4-one 
O
S
O
 
1.8 
0.7 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
According to JECFA: Min. 
assay value is "94" and 
secondary components 
"2,6-Dimethyl-2-[(2-
methyl-3-furyl)thio]-4-
heptanone" 
Composition of mixture to 
be specified. 
13.077 
1085 
3-((2-Methyl-3-furyl)thio)heptan-
4-one 
O
S
O
2.9 
0.7 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.078 
1087 
4-((2-Methyl-3-furyl)thio)nonan-
5-one 
O
S
O
0.73 
0.7 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.079 
1064 
Methyl 2-methyl-3-furyl 
disulfide 
O
S
S
 
0.73 
0.05 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
According to JECFA: Min. 
assay value is "97" and 
secondary components "up 
to 3% bis(2-methyl-3-
furyl)disulfide". 
13.082 
1065 
Propyl 2-methyl-3-furyl disulfide O
S
S
 
0.12 
0.7 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
According to JECFA: Min. 
assay value is "97" and 
secondary components "up 
to 2% bis(2-methyl-3-
furyl)disulfide and propyl 
disulfide". 
13.086 
1089 
4,5-Dihydro-2-methyl-3-
thioacetoxyfuran 
O
S
O
0.49 
0.7 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
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Table 3.3: Summary of Safety Evaluation of 33 sulphur substituted furan derivatives (JECFA, 2002d) considered in FGE.65 (EFSA, 2009an) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
13.093 
1088 
Ethyl 3-(2-
furfurylthio)propionate 
OS
O
O 0.012 
0.2 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.142 
1083 
S-Methyl 2-furanthiocarboxylate 
O
S
O 0.37 
0.1 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
 
13.151 
1082 
2-Methyl-3,5 and 6-
(furfurylthio)pyrazine 
2 or 5 or 6 -Methyl-3-(furfurylthio)pyrazine
N
N
S
O 0.37 
0.7 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
According to JECFA: Min. 
assay value is "99" and 
"Mixture of isomers: 70% 
2,3-; 29% 2,6-; trace 2,5-". 
13.153 
1069 
2-Methyl-3-furyl thioacetate O
S
O
 
0.012 
0.07 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
According to JECFA: Min. 
assay value is "92" and 
secondary components "cis- 
and trans-2-Methyl-3-
tetrahydrofuranthiol 
acetate" 
Composition of mixture to 
be specified. 
13.160 
1090 
2-Methyltetrahydrofuran-3-thiol O
SH
3.5 
0.7 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No adequate NOAEL exists, 
additional data required 
According to JECFA: Min. 
assay value is "97" and 
"71% trans and 26% cis 
isomer". 
13.193 
1091 
2,5-Dimethyltetrahydro-3-
furanthiol 
O
SH  
0.024 
0.9 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No adequate NOAEL exists, 
additional data required 
According to JECFA: Min. 
assay value is "96 (mixture 
of 4 stereoisomers)" 
Composition of mixture to 
be specified. 
13.194 
1092 
2,5-Dimethyltetrahydro-3-furyl 
thio acetate 
O
S
O
 
0.012 
2 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No adequate NOAEL exists, 
additional data required 
According to JECFA: Min. 
assay value is "90 (mixture 
of 4 stereoisomers)" and 
secondary components 
"2,5-
Dimethyltetrahydrofuran-3-
thiol, Dimethyltetrahydro-
3-furyl dithioacetate" 
Composition of mixture to 
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Table 3.3: Summary of Safety Evaluation of 33 sulphur substituted furan derivatives (JECFA, 2002d) considered in FGE.65 (EFSA, 2009an) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the 
named compound 
(Procedure steps, intake 
estimates, NOAEL, 
genotoxicity) 
EFSA conclusion on the 
material of commerce 
be specified. 
13.196 
1084 
4-(Furfurylthio) pentan-2-one 
O
S
O 0.012 
0.6 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
Register name to be 
changed to 4-[(2-
furanylmethyl)thio]-2-
pentanone. 
13.197 
1079 
Furyl propyldisulfide O
S
S
 
0.024 
3 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL 
exists 
4) No safety concern at 
estimated level of intake as 
flavouring substance based 
on the MSDI approach 
Register name to be 
changed to Furfuryl propyl 
disulfide. 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
ND: not determined 
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Table 3.4: Summary of Safety Evaluation of 15 JECFA-Evaluated Furfuryl Derivatives (JECFA, 2001b) considered in FGE.66Rev1 (EFSA, 2011ad) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the named 
compound 
(Procedure steps, intake 
estimates, NOAEL, genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
13.001 
745 
5-Methylfurfural O
O
 
180 
25 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach. 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.002 
746 
Methyl 2-furoate 
O
O
O
 
30 
37 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.003 
747 
Propyl 2-furoate O
O
O
 
0.061 
0.1 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.018 
450 
Furfural O
O
 
440 
460 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.019 
451 
Furfuryl alcohol O
OH
 
180 
24 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach.  Evaluated by JECFA 
before 2000 - No EFSA 
consideration required 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.057 
743 
Furfuryl isovalerate O
O
O
 
0.024 
1 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.062 
740 
Furfuryl propionate O
O
O
 
1.7 
5 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.068 
741 
Furfuryl valerate O
O
O
 
0.24 
14 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.128 
739 
Furfuryl acetate O
O
O
 
16 
21 
Class II 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.005 
749 
Hexyl 2-furoate O
O
O
 
0.061 
0.1 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
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Table 3.4: Summary of Safety Evaluation of 15 JECFA-Evaluated Furfuryl Derivatives (JECFA, 2001b) considered in FGE.66Rev1 (EFSA, 2011ad) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI 1)  
US MSDI 
(μg/capita/day) 
 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound  
[4) or 5)] 
EFSA conclusion on the named 
compound 
(Procedure steps, intake 
estimates, NOAEL, genotoxicity) 
 
EFSA conclusion on the 
material of commerce 
13.025 
748 
Pentyl 2-furoate O
O
O
 
0.36 
0.1 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.038 
752 
2-Phenyl-3-carbethoxyfuran 
O
O
O
0.012 
2 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.067 
742 
Furfuryl octanoate O
O
O
 
0.012 
6 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
13.073 
750 
Octyl 2-furoate O
O
O
 
2.2 
0.1 
Class III 
B3: Intake below threshold,  
B4: Adequate NOAEL exists 
4) No safety concern at the estimated 
level of intake based on the MSDI 
approach 
 No safety concern at the 
estimated level of intake 
based on the MSDI 
approach. 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day., Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
ND: not determined. 
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ABBREVIATIONS 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good laboratory practise 
GSH  Glutathione  
ID  Identity 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NCE  Normochromatic erythrocytes 
No  Number 
NOAEL No observed adverse effect level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PCE  Polychromatic erythrocytes 
SCE  Sister chromatic exchange 
SCF  Scientific Committee on Food 
UDS  Unscheduled DNA synthesis 
WHO  World Health Organisation 
